Upload
others
View
2
Download
0
Embed Size (px)
Citation preview
AUTHOR INDEX FOR VOLUME 22
803
A
Abell, Creed W. See Denney, Patel, and Fritz, 500
Abita, Jean-Pierre. See Gespach, Saal, and Cost, 547
Adams, Stephen M., and Kaminsky, Laurence S. Molecular Orbital
Studies of Epoxide Stability of Carcinogenic Polycyclic Aromatic
Hydrocarbon Diol Epoxides, 459
Adler, A. See Scheibel, 140
Affolter, Hubert, and Pletscher, Alfred. Storage ofBiogenic Amines
in Intact Blood Platelets of Man: Dependence on a Proton Gra-
dient, 94
Aguilar, Jos#{233} S., Salas, Pedro J. I., and De Robertis, Eduardo.
Cholinergic Muscannic Receptor in Synaptosomal Membranes:
Heterogeneity of Binding Sites for L-[H]Quinuclidinyl Benzilate,
304
Aktories, Klaus. See Grandt and Jakobs, 320
Albuquerque, Edson X.See Maleque, Souccar, and Cohen, 636
See Warnick, Jessup, Overman, Eldefrawi, Nimit, and Daly, 565
See Warnick, Maleque, Bakry, and Eldefrawi, 82
Alvares, Alvito P. See Ueng, 221
Anderson, Wendie. See Loew, Hashimoto, Williamson, and Burt,
667
Andersson, Bo, Nordenskj#{246}ld, Magnus, Rahimtula, Anver, and
Mold#{233}us, Peter. Prostaglandin Synthetase-Catalyzed Activation
of Phenacetin Metabolites to Genotoxic Products, 479
Asao, Yukari. See Suketa, Yamada, and Hasegawa, 116
Aslaman, Dimitrina, and de Cheveign#{233}, Suzanne. Inelastic Elec-
tron Tunneling Spectroscopic Study of Interaction of Acetylcho-
line and ,G-Methyl Acetylcholine with Alumina Surface, 678
B
Bader, Hermann. See Gietzen and W#{252}thrich, 413
Baguley, Bruce C., and Cain, Bruce F. Comparison of the in Vito
and in Vitro Antileukemic Activity ofMonosubstituted Derivatives
of 4’-(9-Acridinylamino)methanesulfon-m-anisidide, 486
Bakry, Nabil
Eldefrawi, Ainira T., Eldefrawi, Mohyee E., and Riker, Walter
F., Jr. Interactions of Quaternary Ammonium Drugs with Acetyl-
cholinesterase and Acetyicholine Receptor of Torpedo Electric
Organ, 63
See Warnick, Maleque, Eldefrawi, and Albuquerque, 82
Barber, R. See Clark, Goka, Green, and Butcher, 609
Barsuhn, C. See Cheney, Lahti, and Gay, 349
Batzri, Shmuel
Harmon, John W., and Thompson, William F. Interaction of
Histamine with Gastric Mucosal Cells: Effect of Histamine Ago-
nists on Binding and Biological Response, 33
Harmon, John W., Dyer, Jean, and Thompson, William F.
Interaction of Histamine with Gastric Mucosal Cells: Effect of
Histamine H2 Antagonists on Binding and Biological Response, 41
Baxter, Diane. See Fischer, 231
Beaujouan, J. C., Torrens, Y., Herbet, A., Daguet, M.-C., Glow-
inski, J., and Proehiantz, A. Specific Binding of an Immuno-
reactive and Biologically Active ‘251-Labeled Substance P Deriva-
tive to Mouse Mesencephalic Cells in Primary Culture, 48
Beiderman, Barry. See Bourne, Steinberg, and Brothers, 204
Bend, John R. See Wolf, Statham, McMenamin, Boyd, and Philpot,
738
Boulenger, Jean-Philippe. See Marangos, Patel, and Clark-Rosen-
berg, 26
Bourne, Henry R., Beiderman, Barry, Steinberg, Florence, and
Brothers, Virginia M. Three Adenylate Cyclase Phenotypes in
S49 Lymphoma Cells Produced by Mutations of One Gene, 204
Boyd, Michael R. See Wolf, Statham, McMenamin, Bend, and Phil-
pot, 738
Boyle, Michael R. See Hughes, Brown, Taylor, and Insel, 258
Brothers, Virginia M. See Bourne, Beiderman, and Steinberg, 204
Brown, Oliver E. See Seduick, Hamrell, and Laszlo, 766
Brown, R. Dale. See Hughes, Boyle, Taylor, and Insel, 258
Brune, K. See Mehler and Habicht, 525
Burt, Stanley. See Loeu’, Hashimoto, Williamson, and Anderson,
667
Butcher, R. W. See Clark, Goka, Green, and Barber, 609
C
Cain, Bruce F. See Baguley, 486
Camus, J. See Chatelain, Robberecht, Waelbroeck, De Neef, and
Christophe, 342
Caron, Marc G.
See De Lean and Kilpatrick, 290
See Kilpatrick and De Lean, 298
Carter, Timothy H. See Rose and Leonard, 517
Catterall, William A.
See Costa, 196
See Willow, 627
Cech, Stella Y., and Maguire, Michael E. Magnesium Regulation of
the Beta-Receptor-Adenylate Cyclase Complex. I. Effects of Man-
ganese on Receptor Binding and Cyclase Activation, 267
Chatelain, P., Robberecht, P., Waelbroeck, M., De Neef, P., Ca-
mus, J., and Christophe, J. Thermodependence of Guanine
Nucleotide-Activated Rat Cardiac Adenylate Cyclase Activity: Ef-
fect of Cholera Toxin Pretreatment, 342
Cheney, B. V., Lahti, R. A., Barsuhn, C., and Gay, D. D. An
Analysis of Binding at the Opioid Receptor Based upon an Ago-
nist/Antagonist Two-State Model, 349
Cho, A. K. See Duncan, 235
Cho, Arthur K., Maynard, Michael S., Matsumoto, Richard M.,
Lindeke, Bj#{246}rn, Paulsen, Ulla, and Miwa, Gerald T. The
Opposing Effects of N-Hydroxyamphetamine and N-Hydroxy-
phentermine on the H2O2 Generated by Hepatic Cytochrome P-
450, 465
Christophe, J. See Chatelain, Robberecht, Waelbroeck, De Neef, and
Camus, 342
Chwang, T. Ling. See Roberts, Franklin, Odom, and Peck, 760
Clark, R. B., Goka, T. J., Green, D. A., Barber, R., and Butcher,
R. W. Differences in the Forskolin Activation of Adenylate Cy-
clases in Wild-Type and Variant Lymphoma Cells, 609
Clark-Rosenberg, Reena. See Marangos, Patel, and Boulenger, 26
Clement-Cormier, Yvonne C. See Suen and Kwan, 595
Cohen, Jonathan B. See Maleque, Souccar, and Albuquerque, 636
Coffins, Allan C. See Marks, 554
Conney, Allen H. See Vyas, Levin, Yagi, Thakker, Ryan, Thomas,
and Jerina, 182
Conway, J. G., Kauffman, F. C., Ji, S., and Thurman, R. G. Rates
of Sulfation and Glucuronidation of 7-Hydroxycoumarin in Pen-
portal and Pericentral Regions of the Liver Lobule, 509
Cost, H#{233}l#{232}ne.See Gespach, Saal, and Abita, 547
Costa, Maria R., and Catterall, William A. Characterization of
Variant Neuroblastoma Clones with Missing or Altered Sodium
Channels, 196
Covey, Douglas F. See Klunk and Ferrendelli, 431, 438, 444
Crippen, Gordon M. Distance Geometry Analysis of the Benzodiaze-
pine Binding Site, 11
804 AUTHOR IN1)EX
Crooke, Stanley T. See Long, Willis, and Prestayko, 152
D
Daguet, M.-C. See Beaujouan, Torrens, Herbet, Glowinski, and Pro-
chiantz, 48
Dalmark, Mads, and Johansen, Peter. Molecular Association be-
tween Doxorubicin (Adriamycin) and DNA-Derived Bases, Nu-
cleosides, Nucleotides, Other Aromatic Compounds, and Proteins
in Aqueous Solution, 158
Daly, John W. See Warnick, Jessup, Overman, Eldefrawi, Nimit,
and Albuquerque, 565
Dannan, Ghazi A., and Guengerich, F. Peter. Immunochemical
Comparison and Quantitation of Microsomal Flavin-Containing
Monooxygenases in Various Hog, Mouse, Rat, Rabbit, Dog, and
Human Tissues, 787
Dax, Elizabeth M., and Partilla, John S. Adrenergic Ligand Lipo-
solubiity in Membranes: Direct Assessment in a Beta-Adrenergic
Binding System, 5
de Cheveign#{233}, Suzanne. See Aslanian, 678
De Lean, Andre
Kilpatrick, Brian F., and Caron, Marc G. Dopamine Receptor of
the Porcine Anterior Pituitary Gland: Evidence for Two Affinity
States Discriminated by Both Agonists and Antagonists, 290
See Kilpatrick and Caron, 298
See Vale, Lefkowitz, and Stadel, 619
De Neef, P. See Chatelain, Robberecht, Waelbroeck, Camus, and
Christophe, 342
Denney, Richard M., Patel, Nutan T., Fritz, Richard R., and
Abell, Creed W. A Monoclonal Antibody Elicited to Human
Platelet Monoamine Oxidase: Isolation and Specificity for Human
Monoamine Oxidase B but Not A, 500
De Robertis, Eduardo. See Aguilar and Salas, 304
Diaham, Babou. See Gruenwedel, 121
Duncan, J. D., and Cho, A. K. N-Oxidation of Phentermine to N-
Hydroxyphentermine by a Reconstituted Cytochrome P-450 Oxi-
dase System from Rabbit Liver, 235
Dyer, Jean. See Batzri, Harmon, and Thompson, 41
E
Eldefrawi, Amira T.
Miller, E. Roxanne, Murphy, Deidre L., and Eldefrawi, Mohyee
E. [‘H]Phencyclidine Interactions with the Nicotinic Acetylcholine
Receptor Channel and Its Inhibition by Psychotropic, Antipsy-
chotic, Opiate, Antidepressant, Antibiotic, Antiviral, and Antiar-
rhythmic Drugs, 72
See Bakry, Eldefrawi, and Riker, 63
See Warnick, Maleque, Bakry, and Albuquerque, 82
Eldefrawi, Mohyee E.
See Bakry, Eldefrawi, and Riker, 63
See Eldefrawi, Miller, and Murphy, 72
See Warnick, Jessup, Overman, Nimit, Daly, and Albuquerque, 565
Epand, Richard M. Cation-Induced Conformational Change in Glu-
cagon, 105
Erickson, Leonard C. See Ramonas and McManus, 175
F
Fain, John N. See Litosch, Hudson, Mills, and Li, 109
Ferrendelli, James A. See Kiunk and Covey, 431, 438, 444
Fischer, Paul H., and Baxter, Diane. Enzyme Regulatory Site-
Directed Drugs: Modulation of Thymidine Triphosphate Inhibi-
tion of Thymidine Kinase by 5’-Amino-5’-deoxythymidine, 231
Franklin, Paula. See Roberts, Odom, Peck, and Chwang, 760
Fritz, Richard R. See Denney, Pate!, and Abel!, 500
G
Gay, D. D. See Cheney, Lahti, and Barsuhn, 349
Gespach, Christian, Saal, Fortuna, Cost, H#{233}l#{232}ne,and Abita,
Jean-Pierre. Identification and Characterization of Surface Re-
ceptors for Histamine in the Human Promyelocytic Leukemia Cell
Line HL-60: Comparison with Human Peripheral Neutrophils, 547
Gewirtz, David A., Randolph, Joyce K., and Goldman, I. David.
Catecholamine-Induced Release of the Folic Acid Analogue, Meth-
otrexate, from Rat Hepatocytes in Suspension: An Alpha-Adre-
nergic Phenomenon, 493
Gietzen, Klaus, W#{252}thrich, Andreas, and Bader, Hermann. Effects
of Microtubular Inhibitors on Plasma Membrane Calmodulin-De-
pendent Ca2�-Transport ATPase, 413
Glaumann, Hans. See Thomas, Ryan, von Bahr, and Levin, 190
Glowinski, J. See Beaujouan, Torrens, Herbet, Daguet, and Pro-
chiantz, 48
Goka, T. J. See Clark, Green, Barber, and Butcher, 609
Goldman I. David. See Gewirtz and Randolph, 493
Goren, H. J. See Hanif, Hollenberg, and Lederis, 381
Gorissen, H. See Ilien and Laduron, 243
Grandt, R#{252}diger, Aktories, Klaus, and Jakobs, Karl H. Guanine
Nucleotides and Monovalent Cations Increase Agonist Affinity of
Prostaglandin E2 Receptors in Hamster Adipocytes, 320
Green, D. A. See Clark, Goka, Barber, and Butcher, 609
Gruenwedel, Dieter W., and Diaham, Babou. Methylmercury(II)-
Induced Histone Perturbations in Nuclei Isolated from Calf Thy-
mus, 121
Grunewald, Gary L. See Rafferty, 127
Guengerich, F. Peter. See Dannan, 787
Gylfe, Erik, and Heliman, Bo. Lack of Ca2� Ionophoretic Activity of
Hypoglycemic Sulfonylureas in Excitable Cells and Isolated Secre-
tory Granules, 715
H
Habicht, J. See Mehier and Brune, 525
Hamrell, Michael. See Sedwick, Brown, and Laszlo, 766
Hamf, K., Goren, H. J., Hollenberg, M. D., and Lederis, K. Oxy-
tocin Action: Mechanisms for Insulin-Like Activity in Isolated Rat
Adipocytes, 381
Harden, T. Kendall. See Meeker, 310
Harmon, John W.
See Batzri and Thompson, 33
See Batzri, Dyer, and Thompson, 41
Harrelson, Willard G., Jr., and Mason, Ronald P. Microsomal
Reduction of Gentian Violet: Evidence for Cytochrome P-450-
Catalyzed Free Radical Formation, 239
Harris, R. Adron. See Stokes, 99
Hasegawa, Jun. See Suketa, Yamada, and Asao, 116
Hashimoto, Gail. See Loew, Williamson, Burt, and Anderson, 667
Helhnan, Bo. See Gylfe, 715
Herbet, A. See Beaujouan, Torrens, Daguet, Glowinski, and Pro-
chiantz, 48
Hidaka, Hiroyoshi
See Tanaka and Ohmura, 403
See Tanaka, Ohmura, and Yamakado, 408
Hirsch, James D. See Kochman, 335
Hnatowich, Mark, and LaBella, Frank S. Light-Enhanced Inhibi-
tion of Ouabain Binding to Digitalis Receptor in Rat Brain and
Guinea Pig Heart by the Food Dye Erythrosine, 687
Hollenberg, M. D. See Hanif, Goren, and Lederis, 381
Hom, D. S. See Law and Loh, 1
Houghton, Janet A., Tice, Arvil J., and Houghton, Peter J. The
Selectivity of Action of Methotrexate in Combination with 5-
Fluorouracil in Xenografts of Human Colon Adenocarcinomas, 771
Houghton, Peter J. See Houghton and Tice, 771
Hudson, Thomas H. See Litosch, Mills, Li, and Fain, 109
Hughes, Richard J., Boyle, Michael, R., Brown, R. Dale, Taylor,
Palmer, and Insel, Paul A. Characterization of Coexisting Al-
pha,- and Beta2-Adrenergic Receptors on a Cloned Muscle Cell
Line, BC3H-1, 258
men, B., Gorissen, H., and Laduron, P. M. Characterization of
Solubiized Serotonin (S2) Receptors in Rat Brain, 243
AUTHOR INDEX 805
Insel, Paul A.
See Hughes, Boyle, Brown, and Taylor, 258
See Snavely, 532
J
Jakobs, Karl H. See Grandt and Aktories, 320
Jefcoate, Colin R. See Keller and Turner, 451
Jerina, Donald M. See Vyas, Levin, Yagi, Thakker, Ryan, Thomas,
and Conney, 182
Jessup, Peter J. See Warnick, Overman, Eldefrawi, Nimit, Daly,
and Albuquerque, 565
Ji, S. See Conway, Kauffman, and Thurman, 509
Johansen, Peter. See Dalmark, 158
Johnston, Colin I. See Woodcock, 589
Joost, Hans-Georg, and Steinfelder, Hans-Jurgen. Modulation of
Insulin Sensitivity by Adenosine: Effects on Glucose Transport,
Lipid Synthesis, and Insulin Receptors of the Adipocyte, 614
K
Kaiser, E. T. See Taylor and Miller, 657
Kaminsky, Laurence S. See Adams, 459
Kanter, Peter M., and Schwartz, Herbert S. A Fluorescence En-
hancement Assay for Cellular DNA Damage, 145
Kauffman, F. C. See Conway, Ji, and Thurman, 509
Kellar, Kenneth J. See Schwartz and McGee, 56
Keller, Gabriela M., Turner, Chris R., and Jefcoate, Colin R.
Kinetic Determinations of Benzo[a]pyrene Metabolism to Dihy-
driol Epoxides by 3-Methylcholanthrene-Induced Rat Liver Micro-
somes, 451
Kenimer, James G. See McGee, 360
Kharasch, Evan D., and Novak, Raymond F. Inhibition of Micro-
somal Oxidative Drug Metabolism by 1,4-Bis{2-[2-
hydroxyethyl)amino]-ethylamino)-9,10-anthracenedione Diace-
tate, a New Antineoplastic Agent, 471
Kilpatrick, Brian F.
De Lean, Andre, and Caron, Marc G. Dopamine Receptor of the
Porcine Anterior Pituitary Gland: Effects of N-Ethylmaleimide
and Heat on Ligand Binding Mimic the Effects of Guanine Nu-
cleotides, 298
See De Lean and Caron, 290
Kioss, Michelle W. See Rosen and Rauckman, 529
Kiunk, Wiffiam E.
Covey, Douglas F., and Ferrendelli, James A. Anticonvulsant
Properties of a-, .�‘-, and a,y-Substituted �y-Butyrolactones, 438
Covey, Douglas F., and Ferrendeffi, James A. Comparison of
Epileptogenic Properties of Unsubstituted and fl-Alkyl-Substi-
tuted y-Butyrolactones, 431
Covey, Douglas F., and Ferrendeffi, James A. Structure-Activity
Relationships of Alkyl-Substituted y-Butyrolactones and Succini-
mides, 444
Kochman, Ronald L., and Hirsch, James D. Thermodynamic
Changes Associated with Benzodiazepine and Alkyl f3-Carboline-
3-carboxylate Binding to Rat Brain Homogenates, 335
Koivusaari, Ulla. See Peura, Mackenzie, and Lang, 721
Kwan, Peter C. K. See Suen and Clement-Cormier, 595
L
LaBella, Frank S. See Hnatowich, 687
Laduron, P. M. See Ilien and GorLssen, 243
Lahti, R. A. See Cheney, Barsuhn, and Gay, 349
Lang, Matti. See Peura, Mackenzie, and Koivusaari, 721
Laszlo, John See Sedwick, Hamrell, and Brown, 766
Law, P. Y., Horn, D. S., and Loh, H. H. Loss of Opiate Receptor
Activity in Neuroblastoma x Glioma NG1O8-15 Hybrid Cells after
Chronic Opiate Treatment: A Multiple-Step Process, 1
Lederis, K. See Hanif, Goren, and Hollenberg, 381
Lefl(owitz, Robert J. See Vale, De Lean, and Stadel, 619
Leonard, Thomas B. See Rose and Carter, 517
Levin, Wayne
See Thomas, Ryan, von Bahr, and Glaumann, 190
See Vyas, Yagi, Thakker, Ryan, Thomas, Conney, and Jerina, 182
Li, Shih-Ying. See Litosch, Hudson, Mills, and Fain, 109
Lindeke, Bj#{246}rn. See C/to, Maynard, Matsumoto, Paulsen, and Miwa,
465
Litosch, Irene, Hudson, Thomas H., Mills, Ira, Li, Shih-Ying, and
Fain, John N. Forskolin as an Activator of Cyclic AMP Accu-
mulation and Lipolysis in Rat Adipocytes, 109
Loew, Gilda, Hashimoto, Gail, Williamson, Lenita, Burt, Stanley,
and Anderson, Wendie. Conformational-Energy Studies of
Tetrapeptide Opiates: Candidate Active and Inactive Conforma-
tions, 667
Loh, H. H. See Law and Hom, 1
Lombardini, John B. See Sufrmn, 752
Long, Byron H., Willis, Charles E., Prestayko, Archie W., and
Crooke, Stanley T. Effect of Anthracycline Analogues on the
Appearance of Newly Synthesized Total RNA and Messenger
RNA in the Cytoplasm of Erythroleukemia Cells, 152
Lucier, George W. See Lui, Slaughter, and Philpot, 795
Lui, Edmund M. K., Slaughter, Shelley R., Philpot, Richard M.,
and Lucier, George W. Endocrine Regulation of Cadmium-Sen-
sitive Cytochrome P-450 in Rat Liver, 795
Lukovits, Istv#{225}n. A Theorem on de Novo Group Contributions, 725
M
MacDonald, Timothy, L. See Tachizau’a and Neal, 745
Macfarlane, Donald E.
Bidirectional Collision Coupling in the Regulation of the Adenylate
Cyclase: The Allozyme Hypothesis for Receptor Function, 580
and Stump, David C. Parallel Observation of the Occupancy of the
Alpha2-Adrenergic Receptor in Intact Platelets and Its Ability to
Inhibit the Adenylate Cyclase, 574
Mackenzie, Peter. See Peura, Koivusaari, and Lang, 721
Maguire, Michael E.
Magnesium Regulation of the Beta-Receptor-Adenylate Cyclase
Complex. II. Sc35 as a Mg2� Antagonist, 274
See Cech, 267
M#{228}hlmann, Horst. See Quast and Vollmer, 20
Maleque, Mohammed A.
Souccar, Caden, Cohen, Jonathan B., and Albuquerque, Edson
x. Meproadifen Reaction with the Ionic Channel of the Acetyl-
choline Receptor: Potentiation of Agonist-Induced Desensitization
at the Frog Neuromuscular Junction, 636
See Warnick, Bakry, Eldefrawi, and Albuquerque, 82
Malincomco, Scott M., and McCarl, Richard L Effect of Halothane
on Cardiac Sarcoplasmic Reticulum Ca2�-ATPase at Low Calcium
Concentrations, 8
Marangos, Paul J., Patel, Jitendra, Boulenger, Jean-Philippe,
and Clark-Rosenberg, Reena. Characterization of Peripheral-
Type Benzodiazepine Binding Sites in Brain Using [‘H]Ro 5-4864,
26
Maren, Thomas H. See Sanyal, Swenson, and Pessah, 211
Marks, Michael J., and Collins, Allan C. Characterization of Nico-
tine Binding in Mouse Brain and Comparison with the Binding of
a-Bungarotoxin and Quinuclidinyl Benzilate, 554
Markstein, R. See Seiler, 281
Mason, Ronald P.
See Harrelson, 239
See Mottley and Trice, 732
Matsumoto, Richard M. See Cho, Maynard, Lindeke, Paulsen, and
Miwa, 465
Maynard, Michael S. See Cho, Matsumoto, Lindeke, Paulsen, and
Miwa, 465
McCarl, Richard L. See Malinconico, 8
McGee, Richard, Jr.
and Kenimer, James G. The Effects of Exposure to Unsaturated
Fatty Acids on Opiate Receptors, Prostaglandin E, Receptors, and
806 AUTHOR INDEX
McGee, Richard, Jr.-continued
and Kenimer, James G.-continued
Adenylate Cyclase Activity of Neuroblastoma x Glioma Hybrid
Cells, 360
See Schwartz and Kellar, 56
McManus, Michael E. See Ramonas and Erickson, 175
McMenamin, Mary G. See Wolf, Statham, Bend, Boyd, and Phi Ipot,
738
Meeker, Rick B., and Harden, T. Kendall. Muscarinic Cholinergic
Receptor-Mediated Activation of Phosphodiesterase, 310
Mehler, E. L., Habicht, J., and Brune, K. Quantum Chemical
Analysis of Structure-Activity Relationships in Nonsteroidal Anti-
inflammatory Drugs, 525
Miller, E. Roxanne. See Eldefrawi, Murphy, and Eldefrawi, 72
Miller, Richard J. See Taylor and Kaiser, 657
Mills, Ira. See Litosch, Hudson, Li, and Fain, 109
Miwa, Gerald T. See Cho, Maynard, Matsumoto, Lindeke, and Paul-
sen, 465
Mold#{233}us, Peter. See Andersson, Nordenskjdld, and Rahimtula, 479
Mottley, Carolyn, Trice, Thomas B., and Mason, Ronald P. Direct
Detection of the Sulfur Trioxide Radical Anion during the Horse-
radish Peroxidase-Hydrogen Peroxide Oxidation of Sulfite
(Aqueous Sulfur Dioxide), 732
Murphy, Deirdre L. See Eldefrawi, Miller, and Eldefrawi, 72
Murphy, Kenneth M. M., and Snyder, Solomon H. Heterogeneity
of Adenosine A, Receptor Binding in Brain Tissue, 250
N
Nadler, Hana. See Nehmad and Simantov, 389
Neal, Robert A. See Tachizawa and MacDonald, 745
Nebert, Daniel W. See Tukey and Negishi, 779
Negishi, Masahiko. See Tukey and Nebert, 779
Nehmad, Rafael, Nadler, Hana, and Simantov, Rabi. Effects of
Acute and Chronic Morphine Treatment on Calmodulin Activity
of Rat Brain, 389
Nimit, Yuth. See Warnick, Jessup, Overman, Eldefrawi, Daly, and
Albuquerque, 565
Nordenskj#{246}ld, Magnus. See Andersson, Rahimtula, and Mold#{233}us,
479
Norman, Jon A., and Staehlin, Mattys. Calmodulin Inhibitors Ac-
tivate Glycogen Phosphorylase B to A Conversion in C6 Glioma
Cells, 395
Novak, Raymond F. See Kharasch, 471
0
Odom, Gina. See Roberts, Franklin, Peck, and C/twang, 760
Ohmura, Takehisa
See Tanaka and Hidaka, 403
See Tanaka, Yamakado, and Hidaka, 408
Overman, Larry E. See Warnick, Jessup, Eldefrawi, Nimit, Daly,
and Albuquerque, 565
P
Partilla, John S. See Dax, 5
Patel, Jitendra. See Marangos, Boulenger, and Clark-Rosenberg, 26
Patel, Nutan T. See Denney, Fritz, and Abel!, 500
Paulsen, Ulla. See Cho, Maynard, Matsumoto, Lindeke, and Miwa,
465
Peck, Charles. See Roberts, Franklin, Odom, and Chwang, 760
Pennefather, Peter, and Quastel, David M. J. Modification of Dose-
Response Curves by Effector Blockade and Uncompetitive Antag-
onism, 369
Perez, David J., and Tattersall, Martin H. N. The Metabolic Basis
of Deoxyuridine Cytotoxicity: Studies of Cultured Human Lym-
phoblasts, 166
Pessah, Ness I. See Sanyal, Swenson, and Maren, 211
Peura, Pekka, Mackenzie, Peter, Koivusaari, Ulla, and Lang,
Matti. Increased Fluidity of a Model Membrane Caused by Tet-
rahydro-f.?-Carbolines, 721
Philpot, Richard M.
See Lui, Slaughter, and Lucier, 795
See Wolf, Statham, McMenamin, Bend, and Boyd, 738
Pletscher, Alfred. See Affolter, 94
Prestayko, Archie W. See Long, Willis, and Crooke, 152
Prochiantz, A. See Beaujouan, Torrens, Herbet, Daguet, and Glow-
inski, 48
Q
Quast, Ulrich, M#{228}hlmann, Horst, and Vollmer, Karl-Otto. Tem-
perature Dependence of the Benzodiazepine-Receptor Interaction,
20
Quastel, David M. J. See Pennefather, 369
R
Rafferty, Michael F., and Grunewald, Gary L. The Remarkable
Substrate Activity for Phenylethanolamine N-Methyltransferase
of Some Conformationally Defined Phenylethylamines Lacking a
Side-Chain Hydroxyl Group: Conformationally Defined Adrener-
gic Agents. 6, 127
Rahimtula, Anver. See Andersson, Nordenskj#{244}ld, and Mold#{233}us, 479
Ramonas, Lori M., Erickson, Leonard C., and McManus, Michael
E. The Effect of Misonidazole on the Cytotoxicity and DNA Cross-
Linking Activity of an Activated SuliIdocyclophosphamide in Hy-
poxic Mouse Leukemia Cells, 175
Randolph, Joyce K. See Gewirtz and Goldman, 493
Rauckman, Elmer J. See Rosen and Kioss, 529
Rautanen, P. K. See Vohra, 602
Retz, Konrad C., and Steele, William J. Mechanism of Inhibition of
Protein Synthesis by Morphine in Rat Brain and Liver, 706
Riker, Walter F., Jr. See Bakry, Eldefrawi, and Eldefrawi, 63
Robberecht, P. See Chatelain, Waelbroeck, De Neef, Camus, and
Christophe, 342
Roberts, DeWayne, Franklin, Paula, Odom, Gina, Peck, Charles,
and Chwang, T. Ling. Cytotoxicity of 5-Fluoro-5’-O-nitro-2’-de-
oxyuridine, a New Fluorinated Pyrimidine Derivative, in L1210
Cultures, 760
Rose, Kathleen M., Leonard, Thomas B., and Carter, Timothy H.
Effects of Adenine Nucleosides on RNA Synthesis in Adenovirus-
Infected Cells: 9-fl-D-Arabinofuranosyladenine as a Selective In-
hibitor of RNA Polyadenylation, 517
Rosen, Gerald M., Kloss, Michelle W., and Rauckman, Elmer J.
Initiation of in Vitro Lipid Peroxidation by N-Hydroxynorcocaine
and Norcocaine Nitroxide, 529
Rowe, Elizabeth S. The Effects of Ethanol on the Thermotropic
Properties of Dipalmitoylphosphatidylcholine, 133
Ryan, Dene E.
See Thomas, von Bahr, Glaumann, and Levin, 190
See Vyas, Levin, Yagi, Thakker, Thomas, Conney, and Jerina, 182
S
Saal, Fortuna. See Gespach, Cost, and Abita, 547
Saederup, Else. See Squires, 327
Salas, Pedro J. I. See Aguilar and De Robertis, 304
Sanyal, Gautam, Swenson, Erik R., Pessah, Ness I., and Maren,
Thomas H. The Carbon Dioxide Hydration Activity of Skeletal
Muscle Carbonic Anhydrase: Inhibition by Sulfonamides and An-
ions, 211
Scheibel, L. W., and Adler, A. Antimalarial Activity of Selected
Aromatic Chelators. III. 8-Hydroxyquinolines (Oxines) Substituted
in Positions 5 and 7, and Oxines Annelated in Position 5,6 by an
Aromatic Ring, 140
Schwartz, Herbert S. See Kanter, .145
Schwartz, Rochelle D., McGee, Richard, Jr., and Kellar, Kenneth
J. Nicotinic Cholinergic Receptors Labeled by [3H]Acetylcholine
in Rat Brain, 56
Sedwick, W. David, Hamrell, Michael, Brown, Oliver E., and
Laszlo, John. Metabolic Inhibition by a New Antifolate, 2,4-
Diamino-6- (2,5-dimethoxybenzyl)-5-methyl-pyrido[2,3-d]py-
AUTHOR INDEX 807
rimidine (BW3O1U), an Effective Inhibitor of Human Lymphoid
and Dihydrofolate Reductase-Overproducing Mouse Cell Lines,
766
Seiler, M. P., and Markstein, R. Further Characterization of Struc-
tural Requirements for Agonists at the Striatal Dopamine D-1
Receptor: Studies with a Series of Monohydroxyaminotetralins on
Dopamine-Sensitive Adenylate Cyclase and a Comparison with
Dopamine Receptor Binding, 281
Simantov, Rabi. See Nehmad and Nadler, 389
Slaughter, Shelley R. See Lui, Philpot, and Lucier, 795
Snavely, Marshall D., and Insel, Paul A. Characterization of Alpha-
Adrenergic Receptor Subtypes in the Rat Renal Cortex: Differen-
tial Regulation of Alpha1- and Alpha2-Adrenergic Receptors by
Guanyl Nucleotides and Na�, 532
Snyder, Solomon H. See Murphy, 250
Souccar, Caden. See Maleque, Cohen, and Albuquerque, 636
Squires, Richard F., and Saederup, Else. -y-Aminobutyric Acid
Receptors Modulate Cation Binding Sites Coupled to Independent
Benzodiazepine, Picrotoxin, and Anion Binding Sites, 327
Stadel, Jeffrey M. See Vale, De Lean, and Lefkowitz, 619
Staehlin, Mattys. See Norman, 395
Statham, Charles N. See Wolf, McMenamin, Bend, Boyd, and Phil-
pot, 738
Steele, William J. See Retz, 706
Steinberg, Florence. See Bourne, Beiderman, and Brothers, 204
Steinfelder, Hans-Jurgen. See Joost, 614
Stokes, James A., and Harris, R. Adron. Alcohols and Synaptoso-
mal Calcium Transport, 99
Stump, David C. See Macfarlane, 574
Suen, Erick T., Kwan, Peter C. K., and Clement-Cormier, Yvonne
C. Selective Effects of an Essential Suithydryl Group on the
Activation of Dopamine- and Guanine Nucleotide-Sensitive Ade-
nylate Cyclase, 595
Sufrmn, Janice R., and Lombardini, John B. Differences in the
Active-Site Region of Tumor versus Normal Isozymes of Mars-
malian ATP:L-Methionine S-Adenosyltransferase, 752
Suketa, Yasunobu, Yamada, Masakazu, Hasegawa, Jun, and
Asao, Yukari. A Possible Mechanism for Elevation of Glucose-6-
Phosphatase Activity in Kidney and Liver of Fluoride-Treated
Rats, 116
Swenson, Erik R. See Sanyal, Pessah, and Maren, 211
T
Tachizawa, Haruo, MacDonald, Timothy L., and Neal, Robert A.Rat Liver Microsomal Metabolism of Propyl Halides, 745
Tanaka, Toshio
Ohmura, Takehisa, and Hidaka, Hiroyoshi. Hydrophobic Inter-
action of the Ca2�-Calmodulin Complex with Calmodulin Antago-
fists: Naphthalenesulfonamide Derivatives, 403
Ohmura, Takehisa, Yamakado, Toshiyuki, and Hidaka, Hiro-
yoshi. Two Types of Calcium-Dependent Protein Phosphoryla-
tions Modulated by Calmodulin Antagonists: Naphthalenesulfon-
amide Derivatives, 408
Tank, A. W., and Weiner, N. Induction of Tyrosine Hydroxylase by
Glucocorticoids in Mouse Neuroblastoma Cells: Enhancement of
the Induction by Cyclic AMP, 421
Tattersall, Martin H. N. See Perez, 166
Taylor, John W., Miller, Richard J., and Kaiser, E. T. Structural
Characterization of $-Endorphin through the Design, Synthesis,
and Study of Model Peptides, 657
Taylor, Palmer. See Hughes, Boyle, Brown, and Insel, 258
Thakker, Dhiren R. See Vyas, Levin, Yagi, Ryan, Thomas, Conney,
and Jerina, 182
Thomas, Paul E.
Ryan, Dene E., von Bahr, Christer, Glaumann, Hans, and
Levin, Wayne. Human Liver Microsomal Epoxide Hydrolase:
Correlation oflmmunochemical Quantitation with Catalytic Activ-
ity, 190
See Vya.s, Levin, Yagi, Thakker, Ryan, Conney, and Jerina, 182
Thompson, Wiffiam F.
See Batzri and Harmon, 33
See Batzri, Harmon, and Dyer, 41
Thurman, R. G. See Conway, Kauffman, and Ji, 509
Tice, Arvil J. See Houghton and Houghton, 771
Tolkovsky, A. M. Etorphine Binds to Multiple Opiate Receptors of
the Caudate Nucleus with Equal Affinity but with Different Ki-
netics, 648
Torrens, Y. See Beaujouan, Herbet, Daguet, Glou’inski, and Pro-
chiantz, 48
Trice, Thomas B. See Mottley and Mason, 732
Tukey, Robert H., Negishi, Masahiko, and Nebert, Daniel W.
Quantitation of Hepatic Cytochrome P�-450 with the Use of a
Cloned DNA Probe: Effects of Various P-450 Inducers in C57BL/
6N and DBA/2N Mice, 779
Turner, Chris R. See Keller and Jefcoate, 451
U
Ueng, Tzuu-Huei, and Alvares, Alvito P. Pulmonary Cytochromes
P-450 from Rabbits Treated with 3-Methylcholanthrene, 221
V
Vale, Ronald D., De Lean, Andre, Lefkowitz, Robert J., and
Stadel, Jeffrey M. Regulation of Insulin Receptors in Frog Eryth-
rocytes by Insulin and Concanavalin A: Evidence for Discrete
Classes of Insulin Binding Sites, 619
Vohra, M. M., and Rautanen, P. K. Pharmacological Characteriza-
tion of Histamine Receptors Mediating Cyclic AMP Accumulation
in the Mouse Vas Deferens: Sensitivity to H1 and H2 Receptor
Agonists and Antagonists, 602
Volliner, Karl-Otto. See Quast and Mdhlmann, 20
von Bahr, Christer. See Thomas, Ryan, Glaumann, and Levin, 190
Vyas, Kamlesh P., Levin, Wayne, Yagi, Haruhiko, Thakker,
Dhiren R., Ryan, Dene E., Thomas, Paul E., Conney, Allen
H., and Jerina, Donald M. Stereoselective Metabolism of the
(+)- and (-)-Enantiomers of trans-1,2-Dthydroxy-1,2-Dihydro-
chrysene to Bay-Region 1,2-Diol-3,4-Epoxide Diastereomers by
Rat Liver Enzymes, 182
W
Waelbroeck, M. See Chatelain, Robberecht, De Neef, Camus, and
Christophe, 342
Warnick, Jordan E.
Jessup, Peter J., Overman, Larry E., Eldefrawi, Mohyee E.,
Nimit, Yuth, Daly, John W., and Albuquerque, Edson X.
Pumiiotoxin-C and Synthetic Analogues: A New Class of Nicotinic
Antagonists, 565
Maleque, Mohammed A., Bakry, Nabil, Eldefrawi, Amira T.,
and Albuquerque, Edson X. Structure-Activity Relationships of
Amantadine. I. Interaction of the N-Alkyl Analogues with the
Ionic Channels of the Nicotonic Acetylcholine Receptor and Elec-
trically Excitable Membrane, 82
Weiner, N. See Tank, 421
Williamson, Lenita. See Loew, Hashimoto, Burt, and Anderson, 667
Wiffis, Charles E. See Long, Prestayko, and Crooke, 152
Willow, Max, and Catterall, William A. Inhibition of Binding of
[3H]Batrachotoxinin A 20-a-Benzoate to Sodium Channels by the
Anticonvulsant Drugs Diphenythydantoin and Carbamazepine, 627
Wolf, C. Roland, Statham, Charles N., McMenamin, Mary G.,
Bend, John R., Boyd, Michael R., and Philpot, Richard M.The Relationship between the Catalytic Activities of Rabbit Pul-
monary Cytochrome P-450 Isozymes and the Lung-Specific Tox-
icity of the Furan Derivative, 4-Ipomeanol, 738
Woodcock, Elizabeth A., and Johnston, Colin I. Characterization
of Adenylate Cyclase-Coupled Alpha2-Adrenergic Receptors in
Rat Renal Cortex Using [3H]Yohimbine, 589
W#{252}thrich, Andreas. See Gietzen and Bader, 413
808 AUTHOR INDEX
Y
Yagi, Haruhiko. See Vyas, Levin, Thakker, Ryan, Thomas, Conney,
and Jerina, 182
Yamada, Masakazu. See Suketa, Hasegawa, and Asao, 116
Yamakado, Toshiyuki. See Tanaka, Ohmura, and Hidaka, 408
Yoda, Atsunobu
and Yoda, Shizuko. Formation of ADP-Sensitive Phosphorylated
Intermediate in the Electric Eel Na,K-ATPase Preparation, 693
and Yoda, Shizuko. Interaction between Ouabain and the Phos-
phorylated Intermediate of Na,K-ATPase, 700
Yoda, Shizuko. See Yoda, 693, 700
CUMULATIVE SUBJECT INDEX’ FOR VOLUMES 21 AND 22
809
A
A23187
effect on cyclic AMP, 22, 310
effect on cyclic GMP (guinea pig), 21, 654
Acetaldehyde, effect on membrane fluidity, 22, 721
Acetaniide, interaction with purified liver microsomal isozymes (rab-
bit), 21, 701
4-Acetoxy-4-androstene-3,17-dione, inhibition of estrogen biosynthesis,
21, 173
Acetylcholine
binding, in electroplax membranes (ray), 22, 565
channel noise, 22, 565
interaction with alumina surface, 22, 678
3H-labeledbinding in brain (rat), 22,56
binding to receptor (ray), 22,63
muscarinic analogue, interaction with alumina surface, 22, 678
mcotinic receptor, 21, 351
mcotinic receptor/channel, binding (ray), 22, 63
noise analysis (frog), 22,636
receptor
drug specificity (ray), 22,63
in soleus muscle (rat), 22, 565
ionic channel (frog), 22, 636
ionic channel inactivation (frog), 22, 636
neuromuscular junction (frog), 22, 636
receptor/channel, pharmacology (ray), 22, 72
sensitivity, 22,565
sensitivity (frog), 22, 636
Acetylcholinesterase
edrophonium inhibition (ray), 22,63
inhibition (ray), 22,63
inhibition in Torpedo electric organ, 22,63
N-Acetylglucosaminidase, platelet secretion (human), 21, 422
N-Acetyltransferasecysteine S-conjugate, kidney microsomes (rat), 21, 444
inactivation (hamster), 21, 159
multiplicity (hamster), 21, 159
Aclacinomycin, effect on cytoplasmic RNA in erythroleukemia cells,
22, 152
Acridine derivatives
antileukemic activity, 22, 486
DNA binding, 22, 486
4’-(9-Acridinylamino)methanesulfon-m-anisidide, monosubstituted de-
rivatives, antileukemic activity, 22, 486
Action potential
muscle (frog), 21, 637
skeletal muscle (frog, ray), 22, 82
retardation, 21, 351
Activation, adenylate cyclase, effects ofsulffiydryl groups (dog), 22, 595
Activity
antitumor, 1-(X-phenyl)-3,3-dialkyltriazenes, 21, 187
3-carbomethoxy rifamycin 5, 21, 394
intrinsic, definition in allozyme hypothesis, 22, 580
monooxygenase-like, of tetrameric hemoglobin (rabbit), 21, 1
N-O-Acyltransferase
hepatic (hamster), 21, 159
inactivation (hamster), 21, 159
Addiction, opiate, effects on calmodulin activity (rat), 22, 389
Adenine nucleosides, effects on RNA synthesis, 22, 517
I Boldface numbers indicate appropriate volume; lightface numbers
indicate pagination.
Adenocarcinoma, colon
methotrexate-5-fluorouracil treatment (human), 22, 771
xenografts (human), 22, 771
Adenosine
A,
receptor binding heterogeneity (rat, rabbit, guinea pig, calf, hu-
man), 22, 250
receptor regulation in brain (guinea pig, bovine), 21, 329
antagonism (rat, rabbit, guinea pig, calf, human), 22, 250
effect on glucose transport (rat), 22, 614
effect on insulin receptors (rat), 22, 614
effect on lipid synthesis (rat), 22, 614
modulation of insulin sensitivity (rat), 22, 614
receptor
cation regulation (guinea pig, bovine), 21, 329
guanine nucleotide regulation (guinea pig, bovine), 21, 329
rescue effects in methotrexate-treated cells (human), 21, 718
S-Adenosylhomocysteine
analogues, carboxymethyltransferase inhibition, 21, 181
bindng to hepatocytes (rat), 21, 108
binding to liver plasma membranes (rat), 21, 108
S-Adenosyl-L-methionine, inhibitors of biosynthesis (rat), 22, 752
S-Adenosylmethionine, carboxymethyltransferase inhibition, 21, 181
Adenovirus, RNA synthesis, 22, 517
Adenylate cyclase
activation
by forakolin (human), 21, 680
by forskolin (rat), 22, 109
by forskolin, in lymphoma cells 22, 609
effects of sulihydryl groups (dog), 22, 595
adipocyte, inhibitors, 21, 336
alpha�-adrenergic receptor-coupled, characterization in renal cortex
(rat), 22, 589
alpha inhibition, 21, 17
binding in purified platelet membranes (human), 21, 600
cardiac, thermodependence (rat), 22, 342
compensatory increase, 22, 1
-coupled receptor, anterior pituitary (porcine), 22, 298
coupling proteins, magnesium regulation (mouse), 22, 267
cultured neuroblastoma, 21, 664
dopamine-sensitive (rat), 22, 281
energy of activation (rat), 22, 342
epinephrine inhibition, 22, 574
genetics (mouse), 22, 267, 274
histamine-mediated stimulation in myocardium (human), 21, 671
hormonal inhibition, 21, 336
inhibition, 22, 589
by alpha2-adrenergic receptors (rat), 21, 648
islet cell membrane (rat), 21, 648
La3� inhibition (mouse), 22, 274
lipid incorporation, 21, 492
magnesium regulation (mouse), 22, 267, 274
membrane lipid effects, 22, 360
neuroblastoma cells, opiate inhibition, 21, 483
opiate inhibition, 22, 1
platelet (human), 22, 574
inhibition (human), 21, 609
phenotypes, in 849 lymphoma cells (mouse), 22, 204
receptor coupling, 22, 580
receptor coupling (bovine), 21, 52
receptor coupling (mouse), 22, 204
receptor-mediated inhibition (rat), 21, 570
regulation, 22, 580
renal cortex (rat), 22, 532
810 SUBJECT INDEX
Adenylate cyclase-continuedSc’� inhibition (mouse), 22, 274
stimulation by arachidonic acid metabolites, 21, 664
system, organization (rat), 22, 342
Adipocyte
adenylate cyclase inhibitors, 21, 336
antiipolytic agents, 21, 336
cyclic AMP accumulation (rat), 22, 109
effect of forskolin (rat), 22, 109
effect of hypothyroidism (rat), 22, 109
effect of insulin and adenosine (rat), 22, 614
glucose transport (rat), 22, 614
insulin receptors (rat), 22, 614
lipid synthesis (rat), 22, 614
lipolysis (rat), 22, 109
membrane, adrenergic ligand liposolubiity in (rat), 22, 5
oxytocin action (rat), 22, 381
oxytocin receptor (rat), 22, 381
prostaglandin F42 receptor (hamster), 22, 320
ADP nbosylation, by cholera toxin (mouse), 22, 204
Adrenalectomy, effect on hepatic and renal glucose-6-phosphatase ac-
tivity (rat), 22, 116
Adrenergic ligand
liposolubiity in membranes (rat), 22, 5
n-octanol:water (rat), 22, 5
Adrenergic receptor
alpha-model, 21, 400
role in hepatocyte release of methotrexate (rat), 22, 493
subtype characterization (rat), 22, 532
alpha,-
in submandibular gland (rat), 21, 27
on cloned muscle cell line, coexistence with beta2- (mouse), 22,258
[3H]prazocin (mouse), 22, 258
stimulation in parotid cells (rat), 21, 128
stimulation of phosphatidylinositol-phosphatidic acid turnover
(rat), 21, 128
alpha2-affinity states, 21, 17
binding in purified platelet membranes (human), 21, 600
binding to adenylate cyclase (rat), 22, 589
conformational requirements, 21, 259
coupling to cyclase, 21, 17
cultured hybrid cells, 21, 17
“down regulation” in platelets (human), 21, 36
inhibition of insulin secretion (rat), 21, 648
in neuroblastoma X glioma cells, 21, 17
in submandibular gland (rat), 21, 27
platelet (human), 22, 574
platelet membrane and solubilized preparations (human), 21, 609
beta--adenylate cyclase complex (mouse), 22, 267, 274
agonist affmity (mou.w), 22, 204
binding in erythrocyt.es (frog, turkey), 21, 5
binding system (rat), 22,5
in submandibular gland (rat), 21, 27
interaction with guanine nucleotide binding component (rat), 21,
570
beta2-
[‘251]cyanopindolol (mouse), 22, 258
on cloned muscle cell line, coexistence with alpha,- (mouse), 22,
258
computer modeling, 22, 532
submandibular gland (rat), 21, 27
turnover (mouse), 22, 258
Adriamycin
effect on cytoplasmic RNA in erythroleukemia celLs, 22, 152
hepatic microsomal metabolism (rabbit), 22, 471
molecular associations in aqueous solution, 22, 158
Affinity, agonist, prostaglandin E2 receptors in adipocytes (hamster),
22, 320
Affinity states, dopamine receptors (porcine), 22, 298
Aggregation, stimulus-induced, human platelets, 21, 422
Agonist
acetylcholine receptor, desensitization at neuromuscular junction
(frog), 22, 636
affinity
beta-adrenergic receptors (mouse), 22, 204
prostaglandin E2 receptors in adipocytes (hamster), 22, 320
-antagonist interaction, model, 22, 369
/antagonist two-state binding model, opioid receptor (rat), 22, 349
delta, binding (rat), 21, 564
dopamine, comparison (rat), 21, 114
dopamine receptor, anterior pituitary (porcine), 22, 290
edrophonium (ray), 22, 63
histamine, effect on binding and biological response of gastric mu-
cons! cells (guinea pig), 22, 33
histamine H,, in polymorphonuclear neutrophils (human), 21, 78
histamine H2, in polymorphonuclear neutrophils (human), 21, 78
-induced desensitization, neuromuscular junction (frog), 22, 636
in vivo regulation (chick), 21, 280
mu, binding (rat), 21, 564
muscarinic-induced tremor (rat), 21, 594
opiate, potency and efficacy, 21, 483
platelet alpha2-adrenergic receptor (human), 21, 609
quaternary ammonium (rat), 22, 63
radioligand, binding in neuroblastoma X glioma cells, 21, 17
retained, effect on alpha2-adrenergic receptors in platelets (human),
21, 36
striatal dopamine D-1 receptor, characterization (rat), 22, 281
tetramethylammonium (ray), 22, 63
Albumin, human serum
binding to warfarin, 21, 100
characterization of drug binding area, 21, 387
interaction with cephalosporins, 21, 92
Alcohol, see also Ethanol
effect on free cholesterol transfer in erythrocytes (human), 21, 694
effect on membrane fluidity, 22, 721
dehydrogenase, metabolic compartmentation, 21, 438
neurochemical effects (rat, mouse), 22, 99
Alkaloidopiate, binding in brain (rat), 21, 564
ymca, Ca2�-transport ATPase inhibition (human), 22, 413
N-Alkyl analogues, of amantadine, interaction with mcotinic acetylcho-
line receptor (ray), 22, 82
N-AIkyl compounds, metabolism, 21, 133
Alkyl $-carboline-3-carboxylate binding, brain, thermodynamicchanges (rat), 22, 335
Alkylation, dopamine receptor (bovine), 21, 44
Allosteric interactions in brain (rat), 22, 327
Allozyme hypothesis
definition of intrinsic activity, 22, 580
for receptor function, 22, �8O
Alumina surface, interaction with acetyicholine and ,6-methyl acetyl-
choline, 12, 678
Amantadine, stiucture-activity relationships (ray), 22,82Ames test
for mutagemc potency, 21, 187
1-(X-phenyl)-3,3-dialkyltriazenes, 21, 187
Ametantrone, hepatic microsomal metabolism (rabbit), 22, 471
Amine(s)
aromatic, demethylation, 21, 133
biogenic, storage in intact platelets (human), 22,94lysosomatic, erythrocyte (frog), 22, 619
pump, substrates (rat), 21, 374
Amino acid, a- and N-methyl, conformational analysis (hydra), 21, 629
SUBJECT INDEX 811
in polymorphonuclear neutrophils (human), 21, 78
long-acting (rat, guinea pig), 21, 294
-y-Aminobutyric acid
benzodiazepine receptor regulation (mouse), 21, 618
effect on benzodiazepine binding (rat), 22, 26
effect on [3Hjdiazepam binding (rat), 22, 26
effect on [3H]flumtrazepam binding (rat), 21, 57
-ionophore complex, 21, 320
mimetics, in brain (rat), 22, 327
modulation (rat), 22, 335
receptor, modulation of cation binding sites (rat), 22, 327
p-Aminoclonidine, 3H-labeled
alpha2-adrenergic receptors, 21, 17
binding in purified platelet membranes (human), 21, 600
5’-Amino-5’-deoxythymidine, inhibition of thymidine kinase, 22, 231
2-Amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene, effect on dopa-
mine synthesis (rat), 21, 114
6-Aminolevulinic acid, synthase, effect on organometals (rat), 21, 150
Aminotransferase, tyrosine, hepatic, effect of pregnenolone-16a-carbo-
nitrile (rat), 21, 753
Ammonium
quaternary, agonists and antagonists (ray), 22, 63
quaternary drugs, interactions in Torpedo electric organ, 22, 63
Amphiphiic helices, /1-endorphin, 22, 657
Analgesia
narcotic, 21, 548
opiate (rat), 21, 272
Analogue
acetylcholine, interaction with alumina surface, 22, 678
S-adenosylhomocysteine, 21, 181
binding in liver (rat), 21, 108
N-alkyl, of amantadine, interaction with nicotinic acetylcholine re-
ceptor (ray), 22, 82
clonidine, crystallographic and quantum mechanical analysis, 21,400
folic acid, release from hepatocytes (rat), 22, 493
-y-glutamylcysteinylglycine (hydra), 21, 629
L-methionine, substrate and inhibitory properties (rat), 22, 752
methotrexate, 21, 231
norfenfluramine, conformationally defined, 22, 127
oxytocin, action in adipocytes (rat), 22, 381
phencyclidine (frog), 21, 637
phencyclidine, binding to acetylcholine receptor (ray), 22, 72
phenylethylamines, conformationally defined, 22, 127
synthetic, pumiiotoxin-C, 22, 565
Anesthetic
interaction with benzodiazepine receptors, 21, 320
mechanisms, 22, 133
1-Aniinonaphthalene-8-sulfonic acid, in study of membrane fluidity,
22, 721
Anion
binding sites in brain (rat), 22, 327
inhibition of skeletal muscle carbonic anhydrase (cat), 22, 211
recognition sites in brain (rat), 21, 327
sulfur trioxide radical, direct detection during oxidation of sulfite, 22,
732
Ansamycins, structure-activity relationships, 21, 394
Antagonism, uncompetitive, 22, 369
Antagonistadenosine (rat, rabbit, guinea pig, calf, human), 22, 250
-agonist interaction, model, 22, 369
/agonist two-state binding model, opioid receptor (rat), 22, 349
binding, cooperativity studies (rat), 21, 287
cahnodulin
interaction with Ca2�-ca1modulin complex, 22, 403
phosphorylation modulation, 22, 408
dopamine receptor, anterior pituitary (porcine), 22, 290
edrophonium (ray), 22, 63
histamine H,
histamine H2
effect on binding and biological response of gastric mucosal cells
(guinea pig), 22, 41
in polymorphonuclear neutrophils (human), 21, 78
nicotinic, binding, 22, 565
platelet alpha2-adrenergic receptor (human), 21, 609
radioligand binding in neuroblastoma x glioma cells, 21, 17
regulatory site, 22, 231
quatemary ammonium (ray), 22, 63
Anthracenedione, inhibition of microsomal oxidative drug metabolism
(rabbit), 22, 471
Anthracycline
analogues, cytotoxicity, 22, 152
antitumor effects, 21, 196
effect on cytoplasmic RNA in erythroleukemia cells, 22, 152
inhibition of microsomal oxidative drug metabolism (rabbit), 22, 471
molecular associations, 22, 158
Antiarrhythmic drugs, inhibition of phencyclidine binding (ray), 22, 72
Antibody, monoclonal
distinction of monoamine oxidase A and B, 22, 500
to cytochrome P-45OLM2 and P-45O,�M4, 21, 248
Antibiotics
binding to acetylcholine receptor (ray), 22, 72
inhibition of phencyclidine binding (ray), 22, 72
Anticonvulsant property
a-substituted -y-butyrolactones (mouse, guinea pig), 22, 438
a,-y-substituted y-butyrolactones (mouse, guinea pig), 22, 438
-y-substituted y-butyrolactones (mouse, guinea pig), 22, 438
Anticonvulsantseffect on batrachotoxin binding, 22, 627
interaction with benzodiazepine receptors, 21, 320
Antidepressant drugs, inhibition of phencyclidine binding (ray), 22, 72
Antidepressants, tricyclic, interaction with phencyclidine (ray), 22, 72
Antiestrogen, interaction with muscarinic receptors (rat), 21, 287
Antiherpes, selective agents, 21, 217
Anti-inflammatory drugs
metabolism by neutrophils (rat), 21, 688
nonsteroidal, structure-activity relationships, 22, 525
Antileukemic activity, monosubstituted derivatives of 4’-(9-acndinyl-
amino)methanesulfon-m-anisidide, 22, 486
Antiipolytic agents, adipocyte, 21, 336
Antimalarial agents, lipophilic chelators, 22, 140
Antimetabolic activity, 5-substituted 2’-deoxycytidines, 21, 217
Antimetabolite, antineoplastic, 21, 224
Antineoplastic agent
drug synergism, 21, 224
microsomal inhibition (rabbit), 22, 471
Antinucleoside, immunoreactivity (mouse), 21, 739
Antipsychotic drugs
binding to acetylcholine receptor (ray), 22, 72
inhibition of phencyclidine binding (ray), 22, 72
I Antipsychotics, tricyclic, mitochondrial ATPase inhibition (bovine), 21,
415
Antitumor activity
monosubstituted derivatives, 4’-(9-acridinylamino)methanesulfon-m-
anisidide, 22, 486
1-(X-phenyl)-3,3-dialkyltriazenes, 21, 187
Antitumor effects, of anthracyclines, 21, 196
Antiviral activity, 5-substituted 2’-deoxycytidines, 21, 217
Antiviral drugs
effect on nicotinic acetylcholine receptor (frog, ray), 22, 82
inhibition of phencycidine binding (ray), 22, 72
Anxiolytic drug, quantitative structure-activity relationships, 22, 11
Aorta, surgical stenosis, effect on cardiac muscarinic receptors (rat), 21,
589
Apomorphine
effect on dopamine synthesis (rat), 21, 114
‘H-labeled, dopamine receptor binding (bovine), 21, 44, 52
812 SUBJECT INDEX
9-fl-D-Arabinofuranosyladenine, inhibition of RNA polyadenylation,
22, 517
9-$-D-Arabinofuranosyl-2-fluoroadenine, cytotoxicity, 21, 474
Arachidonic acid
metabolism by neutrophils (rat), 21, 688
metabolites, stimulation of neuroblastoma adenylate cyclase, 21, 664
Aroclor 1254
aryl hydrocarbon hydroxylase induction (rat), 21, 239
7-ethoxycoumarin deethylase induction (rat), 21, 239
Aromataseenzyme catalysis, 21, 173
inhibition, 21, 173
suicide substrates, 21, 173
Aromatic compound, molecular association with Adriamycin, 22, 158
Arylamide N-hydroxylase, liver, modification (rat), 21, 449
Aryl hydrocarbon hydroxylase
Aroclor induction (rat), 21, 239
benzo[a]pyrene oxygenation, 21, 248
microsomal activity (mouse), 22, 779
Arylhydroxamic acid
bioactivation (hamster), 21, 159
suicide inhibitors (hamster), 21, 159
Aspartate transcarbamylase, inhibition, 21, 224
Assay, fluorescence, for cellular DNA damage, 22, 145
Astemizole, binding characteristics (rat, guinea pig), 21, 294
Astrocytoma cellmuscarinic cholinergic receptor (human), 22, 310
phosphodiesterase activity (human), 22, 310
ATP
:L-methiornne S-adenosyltransferase, differences in active-site region
(rat), 22, 752
platelet secretion (human), 21, 422
ATPase
(Ca21, cardiac sarcoplasmic reticulum, effect of halothane (bovine),
22, 8
Ca2�-transport
calmodulin-dependent (human), 22, 413
vinblastine inhibition (human), 22, 413
heart mitochondrial, fluphenazine inhibition (bovine), 21, 415
Atropine, binding in heart (rat), 21, 581
Autonomic receptor, in submandibular gland (rat), 21, 27
Azapropazone, high-affinity binding sites, 21, 387
Aziridinium ions, inhibition of norepinephrine uptake, 21, 380
B
Bacteria, cell wall, penetration by rifamycins, 21, 394
Barbiturates, interaction with benzodiazepine receptors, 21, 320
Batrachotoxin, binding to sodium channels, 22, 627
Bay-region diol epoxide, stereoselective metabolism (rat), 22, 182
BC3H-1, cloned muscle cell line (mouse), 22, 258
Benzo[a]anthracene, induction of cytochrome P-450 (mouse), 22, 779
Benzodiazepine
binding, brain, thermodynamic changes (rat), 22, 335
binding sites
y-aminobutyric acid receptor, modulation (rat), 22, 327
distance geometry analysis, 22, 11
peripheral-type, characterization (rat), 22, 26
pharmacophore, 22, 11
receptor
y-aminobutyric acid regulation (mouse), 21, 618
chloride channel regulation (mouse), 21, 618
heterogeneity (mouse), 21, 618
in brain (rat), 22, 327
ion regulation (mouse), 21, 618
interaction, temperature dependence (rat), 22, 20
interaction with barbiturates, 21, 320
membrane (rat), 21, 57
photoaffinity labeling (mouse), 21, 618
thermodynamics of binding (rat), 22, 20
Benzo[a]pyrene
hydroxylation, 21, 248
metabolism, 21, 248
metabolism (fish), 21, 517
metabolism, kinetic determinants (rat), 22, 451
Benzyl hydrodisufflde, inhibition of liver cytochrome P-450 (rat), 21,
464
Binding
acetylcholine, in electroplax membranes (ray), 22, 565
acridine derivatives, by DNA, 22, 486
adenosine A, receptors, species heterogeneity (rat, rabbit, guinea pig,
calf, human), 22, 250
S-adenosylhomocysteine, in liver (rat), 21, 108
alkyl /?-carboline-3-carboxylate, brain, thermodynamic changes (rat),
22, 335
antiestrogen (rat), 21, 287
batrachotoxin, inhibition 22, 627
benzodiazepinebrain, thermodynamic changes (rat), 22, 335
characterization of peripheral-type sites (rat), 22, 26
thermodynamics (rat), 22, 20
beta-adrenergic system (rat), 22, 5
a-bungarotoxin, in brain (mouse), 22, 554
carbamylcholine, in electroplax membranes (ray), 22, 565
cation, to glucagon, 22, 105
delta agonist (rat), 21, 564
DNA, correlation with anthracycline antitumor potency, 21, 196
[3H]dopamine, caudate nucleus (calf), 22, 281
dopamine D-1 receptor, characterization (rat), 22, 281
enthalpy, brain homogenates (rat), 22, 335
enthalpy-driven (rat), 22, 20
entropy, brain homogenates (rat), 22, 335
entropy-driven (rat), 22, 20
equilibrium, [3H]diazepam, 21, 320
etorphine, opiate receptors of caudate nucleus (sheep), 22, 648
[3H]etorphine
in vitro, 21, 548
receptor in vivo (rat), 21, 272
gastric mucosal cells
effect of histamine agonists (guinea pig), 22, 33
effect of histamine H2 antagonists (guinea pig), 22, 41
GTP regulatory protein (bovine), 21, 52
in vitro, characteristics, 21, 294
in vivo, characteristics (rat, guinea pig), 21, 294
[3H}ketanserin (rat), 21, 301
kinetics
association and dissociation (rat), 21, 57
human serum albumin, 21, 100
[3H]leucine enkephalin
effect of morphine (rat), 21, 538
in vitro, 21, 548
ligand, 21, 558
3H-ligand, effect of heat treatment (bovine), 21, 52
long-acting H1 antagonist (rat, guinea pig), 21, 294
mu agonist (rat), 21, 564
muscarinic receptor
aceclidine and its methiodide (rat), 21, 594
in brain (rat), 21, 594
nicotine, in brain (mouse), 22, 554
nicotinic acetylcholine receptor/channel (ray), 22, 63
nonspecific, saxitoxin, 21, 343
opiate receptor, 21, 483, 492
in brain (rat), 21, 564
opioid receptor, two-state model (rat), 22, 349
ouabain, to digitalis receptor (rat, guinea pig), 22, 687
[3H}n-propylapomorphine, in pituitary (porcine), 22, 290, 298
protein, human serum albumin, 21, 100
SUBJECT INDEX 813
quinucidinyl benzilate, in brain (mouse), 22, 554
radioligand
computer modeling, 21, 5
in submandibular gland (rat), 21, 27
receptor
$-endorphin models, 22, 657
guanine nucleotide regulation (hamster), 22, 320
monovalent cations (hamster), 22, 320
site
anion, in brain (rat), 22, 327
benzodiazepine, distance geometry analysis, 22, 11
benzodiazepine, in brain (rat), 22, 327
cardiac, effects of guanine nucleotides (rat), 21, 581
cation, y-aminobutyric acid modulation (rat), 22, 327
characterization, 21, 387
high-affinity, azapropazone, 21, 387
high-affinity, warfarin, 21,387insulin, in erythrocytes (frog), 22, 619
opiates, 21, 266
picrotoxin, in brain (rat), 22, 327
saxitoxin, structure, 21, 343
sodium channels in nerve membranes, 21, 343
spiperone, in brain (rat), 22, 243
[3H]spiroperidol
caudate nucleus (calf), 22, 281
pituitary (porcine), 22, 290, 298
substance P derivative, to mesencephalic cells (mouse), 22, 48
toxin molecules, exchange of tritium, 21, 343
two-site model (cat), 22, 304
zinc, to glucagon, 22, 105
Biogenic amines, storage in intact platelets (human), 22, 94
Biosynthesis
estrogen, inhibition, 21, 173
prostaglandin, N-alkylation during, 21, 133
Bisbenzamide, assay for cellular DNA damage, 22, 145
1,4-Bis(2-[(2-hydroxyethyl)amino]-ethylamino)-9,10-anthracenedione
diacetate, inhibition of microsomal oxidative drug metabolism
(rabbit), 22, 471
Bladder, urinary, water flow (toad), 21, 142
Blood platelets, storage of biogenic amines (human), 22, 94
Blot hybridizationDNA (mouse), 22, 779
mRNA (mouse), 22, 779
Brain
[3Hjacetylcholine binding sites (rat), 22, 56
adenosine A, receptor binding, species heterogeneity (rat, rabbit,
guinea pig, calf, human), 22, 250
adenylate cyclase, effects of sulhydryl groups (dog), 22, 595
alkyl fl-carboline-3-carboxylate binding (rat), 22, 335
y-aminobutyric acid receptors (rat), 22, 327
ATP concentration, effect of morphine (rat), 22, 706
benzodiazepine
binding (rat), 22, 335
binding, characterization of peripheral-type sites (rat), 22, 26
receptors (mouse), 21, 618
receptors (rat), 22, 327
digitalis receptor, inhibition of ouabain binding (rat), 22, 687
effects of morphine treatment on calmodulin activity (rat), 22, 389
embryonic, muscarinic receptors (chick), 21, 280
[3H]ketanserin distribution (rat), 21, 301
membrane, opiate binding (rat), 21, 564
nicotinic cholinergic receptors (rat), 22, 56
particulate fraction, [‘H]leucine enkephalin binding (rat), 21, 538
protein synthesis inhibition by morphine (rat), 22, 706
serotonin receptors, characterization (rat), 22, 243
spiperone binding (rat), 22, 243
5-Bromo-2’-deoxycytidine, antiherpes activity, 21, 217
(E)-5-(2-Bromovinyl)-2’-deoxycytidine, antiviral and antimetabolic
properties, 21, 217
(E)-5-(2-Bromovinyl)-2’-deoxyuridine
differential antiviral activity, 21, 432
phosphorylation, 21, 432
a-Bungarotoxin
binding in brain (mouse), 22, 554
receptor, binding in brain (mouse), 22, 554
y-Butyrolactone
alkyl-substituted, structure-activity relationships (mouse, guinea
pig), 22, 444
a-substituted, anticonvulsant properties (mouse, guinea pig), 22, 438
a,y-substituted, anticonvulsant properties (mouse, guinea pig), 22,
438
$-alkyl-substituted, eleptogenic properties (mouse, guinea pig), 22,
431
-y-substituted, anticonvulsant properties (mouse, guinea pig), 22, 438
unsubstituted, eleptogenic properties (mouse, guinea pig), 22, 431
C
Ca2�, see also Calcium
-ATPase, cardiac sarcoplasmic reticulum, effect of halothane (bo-
vine), 22, 8
-calmodulin-dependent phosphorylation, 22, 408
-calmodulin complex, interaction with calmodulin antagonists, 22,
403
-H� exchange diffusion (mouse), 22, 715
ionophore
effect on cyclic AMP, 22, 310
hypoglycemic sulfonylureas (mouse), 22, 715
phospholipid-dependent phosphorylation, 22, 408
-transport ATPase, calmodulin-dependent (human), 22, 413
Cadmium-sensitive hepatic cytochrome P-450 (rat), 22, 795
Calcium, see also Ca2�
effect of halothane at low concentrations (bovine), 22, 8
platelet secretion (human), 21, 422
stimulus-induced mobilization in human platelets, 21, 422
transport
in excitable cells (mouse), 22, 715
in isolated secretory granules (mouse), 22, 715
uptake
glutamate-stimulated (rat, mouse), 22, 99
potassium-stimulated (rat, mouse), 22, 99
synaptosomal (rat, mouse), 22, 99
Calmodulin
antagonist
effect on human platelets, 21, 422
interaction with Ca2�-calmodulin complex, 22, 403
phosphorylation modulation, 22, 408
-Ca2� complex, interaction with calmodulin antagonists, 22, 403
effects of morphine treatment (rat), 22, 389
-dependent Ca2�-transport ATPase (human), 22, 413
human platelet, effect of trifluoperazine, 21, 422
inhibition (bovine), 21, 86
inhibitors, in C6 glioma cells, 22, 395
vinblastine binding (human), 22, 413
Carbachol
cyclic GMP stimulation (guinea pig), 21, 654
effect on cultured thyroid cells (porcine), 21, 66, 73
fatty acid hydroperoxides, cyclic GMP (guinea pig), 21, 654
-induced desensitization, cultured thyroid cells (porcine), 21, 73
phospholipase A2 stimulation (guinea pig), 21, 654
Carbamazepine, effect on batrachotoxin binding, 22, 627
Carbamoylation, in nitrosourea cytotoxicity (rat), 21, 729
Carbamylcholine binding
in electroplax membranes (ray), 22, 565
in heart (rat), 21, 581
Carbomethoxy, stereospecificity at position 10, 21, 196
lethality
5-fluorouracil (human), 21, 468
5-fluorouridine (human), 21, 468
leukemia, hypoxic, synergistic toxicity of misomdazole and sulfido-
cyclophosphamide (mouse), 22, 175
lymphoblast, deoxyuridine metabolism (human), 22, 166
mesencephalic, substance P derivative binding (mouse), 22, 48
methotrexate-treated, 21, 204
rescue effects of folinic acid and glycine, adenosine, and thymidine
(human), 21, 718
morphological transformation (mouse), 21, 739
muscle, cloned, BC3H-l (mouse), 22, 258
neuroblastoma
serotonin uptake, 21, 362
tyrosine hydroxylase induction (mouse), 22, 421
neuroblastoma N18TG2
opiate inhibition, 21, 483
potentiation of opiate action, 21, 492
neuroblastoma x glioma hybrid, adenylate cyclase activity, 22, 360
neuroblastoma x glioma NG1O8-15 hybrid
opiate inhibition, 21, 483
opiate receptor activity, 22, 1
neuronal, culture (mouse), 22, 48
parotid, phosphatidylinositol-phosphatidic acid turnover (rat), 21,
128
3-Carbomethoxy rifamycin 5, molecular structure by ‘H NMR and X-
rays, 21, 394
Carbon-centered free radical (rat), 22, 239
Carbon dioxide, hydration activity of skeletal muscle (cat), 22, 211
Carbonic anhydrase, skeletal muscle, carbon dioxide hydration activity
(cat), 22, 211
Carboxymethyltransferase, synaptosomal, inhibition (calf, rat), 21, 181
Carcinogen, chemical, phenacetin, 22, 479
Carcinogenesis, role of bay-region diol epoxide (rat), 22, 182
Carcinogenicity, polycyclic aromatic hydrocarbons, 22, 459
Carcinoma
colon, cultured cells (human), 21, 468
selective cytotoxicity of haloethylnitrosoureas (rat), 21, 729
Walker 256 (rat), 21, 729
Cardiotoxicity, anthracycline antineoplastic agents, 22, 471
Carminomycin, effect on cytoplasmic RNA in erythroleukemia cells,
22, 152
Catalysis, aromatase enzyme, 21, 173
Catalytic activity
liver microsomal epoxide hydrolase (human), 22, 190
pulmonary cytochrome P-450 isozymes (rabbit), 22, 738
Catecholamine
effect on adenylate cyclase in myocardium (human), 21, 671
effect on binding in platelets (human), 21, 609
effect on binding in purified platelet membranes (human), 21, 600
effect on ion fluxes in erythrocytes (turkey), 21, 503
-induced release of methotrexate from hepatocytes (rat), 22, 493
receptor, binding in erythrocytes (frog, turkey), 21, 5
Cation
binding, glucagon, 22, 105
binding sites, y-aminobutyric acid modulation (rat), 22, 327
fluxes, in erythrocytes (turkey), 21, 503
monovalent
effect on binding in platelets (human), 21, 609
effect on binding in purified platelet membranes (human), 21, 600
effect on prostaglandin E2 receptors in adipocytes (hamster), 22,
320
receptor regulation (guinea pig, bovine), 21, 329
recognition sites in brain (rat), 22, 327
Caudate membrane, 3H-ligand binding sites (bovine), 21, 44, 52
Caudate nucleus, opiate receptors, etorphine binding (sheep), 22, 648
Cellantinucleoside immunoreactivity (mouse), 21, 739
astrocytoma
muscarinic cholinergic receptor (human), 22, 310
phosphodiesterase activity (human), 22, 310
carcinoma
in culture (human), 21, 468
resistance to bifunctional nitrogen mustards (rat), 21, 729
selective toxicity of haloethylnitrosoureas (rat), 21, 729
culture, L1210 leukemia, 22, 486
cycle, effect of methotrexate, 21, 204
cytochrome P-450, effect of organometals (rat), 21, 150
differentiation (human), 22, 547
DNAfluorescence assay for damage, 22, 145
strand separation (mouse), 21, 739
erythroleukemia, RNA transport, 22, 152
excitable, calcium transport (mouse), 22, 715
gastric mucosa, interaction with histamine (guinea pig), 22, 33, 41
glioma C6
calmodulin inhibitors, 22, 395
glycogen phosphorylase conversion B to A, 22, 395
HeLa, 9-$-D-arabinofuranosyl-2-fluoroadenine inhibition (human),
21, 474
KB
dihydrofolate reduct.ase (human), 21, 231
methotrexate-resistant (human), 21, 231, 248
serotonin uptake, 21, 368
proliferation (human), 22, 547
promyelocytic leukemia HL-60 (human), 22, 547
5180 AT/3000, dihydrofolate reductase (mouse), 21, 231
549 lymphoma, adenylate cyclase phenotypes (mouse), 22, 204
thyroid
culture (porcine), 21, 66, 73
muscarinic cholinergic receptors on (porcine), 21, 66, 73
Central nervous system
depressant drugs, 21, 320
receptors, in vitro, 21, 315
substance P binding (mouse), 22, 48
Cephalosporin, interaction with human serum albumin, 21, 92
Cerebroside sulfate, acidic lipids, 21, 492
CF 25-397, see 9, l0-Didehydro-6-methyl-3$- (2-pyridylthiomethyl)-
ergoline
Channel noise, acetylcholine, 22, 565
Chelator, lipophiic, antimalarial activity, 22, 140
CHEMLAB, triazene mutagenicity analysis, 21, 187
Chemotherapy, drug design, 22, 231
Chioramphenicol, cytochrome P-450 inactivation (rat), 21, 166
Chloride channel, benzodiazepine receptor regulation (mouse), 21, 618
N-2’-Chloroethyl-N-ethyl-2-methylbenzylamine, chemical transforma-
tions in solution, 21, 380
N-2’-Chloroethyl-2-methylbenzylamine, inhibition of norepinephrine
uptake, 21, 380
1-Chloro-2,2,2-trifluoroethyl radical, binding to phospholipids (human,
rabbit), 21, 710
Chlorpromazine, ring sulfoxidation, 21, 409
Cholera toxin
ADP ribosylation (mouse), 22, 204
effect on cardiac adenylate cyclase activity (rat), 22, 342
Cholesterol, free, transfer into erythrocytes (human), 21, 694
Cholic acid, sodium salt, effect on opiate binding (rat), 21, 564
Cholinergic receptor
muscarinic (mouse), 22, 554
nicotinic (mouse), 22, 554
Chromaffin granules, calcium transport (mouse), 22, 715
Chromatin, thymus
formaldehyde cross-linking (calf), 22, 121
methylmercury complexes (calf), 22, 121
814 SUBJECT INDEX
pheochromocytoma
norepinephrine uptake, 21, 368
SUBJECT INDEX 815
L1210 leukemia cells, 22, 486
Lymphoblasts, deoxyuridine metabolism (human), 22, 166
Chromatography
column, pulmonary cytochrome P-450 (rabbit), 22, 221
high-pressure liquid, benzo[a]pyrene metabolism, 21, 248
Chromosomemarkers, in nitrosourea cytotoxicity (rat), 21, 729
modal number (rat), 21, 729
Chrysene 1,2-dihydriols, stereoselective metabolism (rat), 22, 182
Circular dichroism, glucagon, 22, 105
Clomiphene, interaction with muscarinic receptors (rat), 21, 287
ClonecDNA, for P,-450 (mouse), 22, 779
muscle cell line, BC3H-1 (mouse), 22, 258
neuroblastoma variants, characterization, 22, 196
Clonidine, pharmacology, 21, 400
Cocaine metabolite, hepatotoxicity (rat, hamster), 21, 458
Colchicine, effect on urinary bladder (toad), 21, 142
Colon
adenocarcinoma
methotrexate-5-fluorouracil treatment (human), 22, 771
xenografts (human), 22, 771
carcinoma, cultured cells (human), 21, 468
xenografts, selectivity (human), 22, 7711
Complex
cephalosporin-human serum albumin, 21,92
metabolic-intermediate, cytochrome P-450, from isosafrole (rat), 21,
527
Computer modeling
adrenergic receptors, 22, 532
for radioligand binding data, 21, 5
Computerized curve-fitting technique, discrimination ofopiate receptor
binding sites, 21, 266
Concanavalin A, regulation of insulin receptors in erythrocytes (frog),
22, 619
Conformation
-energy calculations, 22, 667
interconvertible, benzodiazepine receptor (rat), 21, 57
sodium channel, 21,343
Conformational analysis
a- and N-methyl amino acids (hydra), 21,629
l-(Lphenyl)-3,3-dialkyltriazenes, 21, 187
Conformational change, glucagon, 22, 105
Conformational model, two-state, for phenylethanolamine N-methyl-
transferase, 22, 127
Conformational preference, phenylethanolamine N-methyltransferase
substrates, 22, 127
Conformational requirements, alpha2-adrenergic receptors, 21, 259
Conformer, active/inactive, 22, 667
Constant, high metal binding, oxine, 22, 140
Cooperativity
antiestrogen with muscarinic receptors (rat), 21, 287
lipid transition, 22, 133
Co-oxidation, prostaglandin synthetase, 21, 133
Correlation, dopamine-sensitive adenylate cyclase/[’H]dopamine bind-
ing, 22, 281
Cortex, cerebral, synaptosomal membranes (rat), 21, 57
Coupling
collision, bidirectional, to adenylate cyclase, 22, 580
factor, definition, 22, 580
receptors to adenylate cyclase, 22, 580
Cross-reaction minimalization, opiate alkaloid and peptide, by man-
ganese (rat), 21, 564
Crystallographic analysis, clonidine, 21, 400
Culturecarcinoma cells (human), 21, 468
L1210 cells, cytotoxicity of 5-fluoro-5’-O-nitro-2’-deoxyuridine, 22,
760
neuroblastoma cells
adenylate cyclase, 21, 664
serotonin uptake, 21, 362
neuronal cells (mouse), 22, 48
pheochromocytoma cells
norepinephrine uptake, 21, 368
serotonin uptake, 21, 368
primary, mesencephalic cells (mouse), 22, 48
Current, end-plate
amplitude, 22, 565
decay, 22, 565
Curve-fitting technique, computerized, discrimination of opiate recep-
tor binding sites, 21, 266
Cyanopindolol, 3H-labeled, beta2-adrenergic receptor (mouse), 22, 258
Cyclic AMP
accumulation in adipocytes (rat), 22, 109
accumulation in lymphoma cells, 22, 609
accumulation in van deferens (mouse), 22, 602
degradation in astrocytoma cells (human), 22, 310
enhancement of tyrosine hydroxylase induction (mouse), 22, 421
forskolin activation (rat), 22, 109
generation in pancreatic islets (rat), 21, 648
in promyelocytic leukemia cells (human), 22, 547
levels in cultured thyroid cells (porcine), 21, 66
myocardial (human), 21, 671
neuroblastoma cell (mouse), 22, 421
platelet levels (human), 21, 680
inhibition by forskolin, 21, 680
polymorphonuclear neutrophils (human), 21, 78
protein kinase (rat), 21, 121
receptors, in erythrocytes (turkey), 21, 503
Cyclic GMP, carbachol stimulatory effect (guinea pig), 21, 654
Cyclohexyladenosine, 3H-labeled, binding to adenosine A, receptors in
brain (guinea pig, bovine), 21, 329
Cyclooxygenase, metabolism of arachidonic acid by neutrophils (rat),
21, 688
Cysteine, S-conjugate N-acetyltransferase, kidney microsomes (rat),
21,444
Cytochrome
b5, substrate interaction (rabbit), 21, 701
P-450
cardiac microsomes (fish), 21, 517
cellular, effect of organometals (rat), 21, 150
content in neonatal skin (rat), 21, 239
effects of cadmium (rat), 22, 795
electrophoresis, 22, 787
‘H Fourier transform studies (rabbit), 21, 701
H2O2 generation by hydroxylamines (rat), 22, 465
hepatic, alkyl halide metabolism (rat), 22, 745
hepatic, cadmium-sensitive (rat), 22, 795
hepatic, immunochemistry (rat), 21, 753
hepatic, inactivation (rat), 21, 166
hepatic, induction with pregnenolone-16a-carbonitrile (rat), 21,
753
hepatic, neonatal imprinting and (rat), 21, 744
hepatic, neonatally imprinted forms (rat), 21, 744
hepatic, opposing effects of N-hydroxyamphetamine and N-hy-
droxyphentermine (rat), 22, 465
hepatic, reconstituted (rabbit), 22, 235
hepatic, reduction of gentian violet (rat), 22, 239
hepatic, sex-dependent forms (rat), 21, 744
hepatic, stereoselective metabolism (rat), 22, 182
hepatic, turnover (rat), 21, 744
immunochemical studies (rat), 21, 744
induction, genetic differences (mouse), 22, 779
inhibition by benzyl hydrodisulfide (rat), 21, 464
metabolic-intermediate complexes from isosafrole (rat), 21, 527
microsomal, of skin, dermis, and epidermis (rat), 21, 239
816 SUBJECT INDEX
Cytochrome-continued
P-450-continued
multiple forms (rat), 22, 795
NADPH reductase, hepatic microsomal (rabbit), 22, 471
N-oxidation of phentermine (rabbit), 22, 235
pulmonary, isozymes (rabbit), 22, 738
pulmonary, 3-methylcholanthrene induction (rabbit), 22, 221
pulmonary, multiple forms (rabbit), 22, 221
pulmonary, role in toxicity of 4-ipomeanol (rabbit), 22, 738
pulmonary, spectral and electrophoretic properties (rabbit), 22,
221
radical formation (rat), 22, 239
reductive metabolism of halothane (human, rabbit), 21, 710
sex differentiation (rat), 22, 795
subpopulations, induction by isosafrole (rat), 21, 527
subpopulations, induction by /3-naphthoflavone (rat), 21, 527
subpopulations, induction by phenobarbit.al (rat), 21, 527
substrate interaction (rabbit), 21, 701
P-450,,,, 3-methylcholanthrene induction (rabbit), 22, 221
P-45OLM2, monoclonal antibodies to, 21, 248
P-45OLM4, monoclonal antibodies to, 21, 248
P,-450
messenger RNA (mouse), 22, 779
protein (mouse), 22, 779
Cytometry, flow, deoxyuridine treatment in lymphoblasts (human), 22,
166
Cytoplasm, RNA, effect of anthracyclines, 22, 152
Cytotoxicity, see also Toxicity
anthracycline analogues, 22, 152
deoxyuridine (human), 22, 166
5-fluorodeoxyuridine, 21, 211
in gastrointestinal tumor (human), 21, 723
5-fluoro-5’-O-nitro-2’-deoxyuridine, in L1210 cultures, 22, 760
methotrexate, 21, 204
methotrexate (human), 21, 718
in gastrointestinal tumor, 21, 723
misonidazole (mouse), 22, 175
selective, haloethylnitrosoureas in carcinoma (rat), 21, 729
5-substituted 2’-deoxycytidines, 21, 217
D
Daunomycin, effect on cytoplasmic RNA in erythroleukemia cells, 22,
152
Deactivating system, basal, postulated, 22, 580
Decomposition, superoxide spin-trapped adducts, 21, 262
Dehydrogenase, alcohol, metabolic compartmentation, 21,438
Dehydrogenase, NADH, hepatic microsomal (rabbit), 22, 471
De novo constants, correlations between, 22, 725
Depressant drugs, interaction with benzodiazepine receptors, 21, 320
3’-Deoxyadenosine, effect on RNA synthesis, 22, 517
2’-Deoxycytidines, 5-substituted, antiviral, antimetabolic, and cytotoxic
activities, 21, 217
Deoxyuridine
cytotoxicity (human), 22, 166
phosphates, cytosol, 21, 224
4-Demethoxydaunomycin, effect on cytoplasmic RNA in erythroleu-
kemia cells, 22, 152
Desensitization
cultured thyroid cells (porcine), 21, 73
neuromuscular junction (frog), 22, 636
Desmethylimipramineinhibition of norepinephrine uptake, 21, 368
inhibition of serotonin uptake, 21, 362, 368
Dexamethasone, induction of hepatic cytochrome P-450 (rat), 21, 753
Dexetimide, inhibition of binding in heart (rat), 21, 581
Dialysis, equilibrium, cephalosporin-human serum albumin complexes,
21, 92
2,4-Diamino-6-(2,5-dimethoxybenzyl)-5-methyl-pyrido[2,3-djpyrimi-
dine, metabolic inhibition (mouse), 22, 766
Diarachidonyl diglyceride, formation by neutrophils (rat), 21, 688
Diazepam, ‘H-labeled, equilibrium binding, 21, 320
9,10-Didehydro-6-methyl-3$-(2-pyridylthiomethyl)ergoline, effect on
dopamine synthesis (rat), 21, 114
fl-Diethylaminoethyl-2,2-diphenylpentanoate, translocation of estrogen
receptor (rat), 21, 533
Diethylphenylxanthine, ‘H-labeled, binding to adenosine A, receptors
in brain (guinea pig, bovine), 21, 329
Differentiation, cellular (human), 22, 547
Digitalis receptor, light-enhanced inhibition ofbinding (rat, guinea pig),
22, 687
Diglyceride, diarachidonyl, formation by neutrophuls (rat), 21, 688
Dihydriol epoxide, formation in liver (rat), 22, 451
Dihydroalprenolol, 3H-labeled
adipocyte membranes (rat), 22, 5
binding in erythrocytes (frog, turkey), 21, 5
Dihydrofolate reductase
effect of methotrexate (human), 21, 478
in human KB cells, 21, 231
mouse cell lines, inhibition by antilolate BW3O1U, 22, 766
Dihydromorphine, ‘H-labeled, binding in brain (rat), 22, 349
Dihydroxyaminotetralins, effect on dopamine receptor binding (rat),
22, 281
3,4-Dihydroxyphenylamino-2-jmidazoline, effect on dopamine synthe-
sis (rat), 21, 114
5,6-Dihydroxytryptamine, cytotoxic effect, 21, 362, 368
5,7-Dihydroxytryptamine, cytotoxic effect, 21, 362, 368
Dimer, enkephalin, affinity and selectivity for delta opiate receptor, 21,
558
Dimethylaniline N-oxidase, quantitation, 22, 787
Diol epoxide, bay-region, stereoselective metabolism (rat), 22, 182
Dipalmitoylphosphatidylcholine
model membrane, fluidity, 22, 721
thermotropic properties, effects of ethanol, 22, 133
transitions, 22, 133
Diphenylhydantoin, effect on batrachotoxin binding, 22, 627
Diprenorphine, 3H-labeled, binding in intact cells, 22, 1
Distance geometry, benzodiazepine binding site, 22, 11
Diterpene, forskolin, effect on platelets (human), 21, 680
DNA
adduct, hepatic (rat), 22, 451
binding
correlation with anthracycline antitumor potency, 21, 196
correlation with nucleic acid synthesis inhibition, 21, 196
complementary, cloned, for P,-450 (mouse), 22, 779
cross-linking, in hypoxic leukemia cells (mouse), 22, 175
damage
fluorescence assay, 22, 145
phenacetin metabolite-induced, 22, 479
-dependent RNA polymerase, inhibition by rifamycins, 21, 394
-derived bases, molecular associations with Adriamycin, 22, 158
drug binding, acridine derivatives, 22, 486
5-fluorouracil incorporation, 21, 211
fragmentation and repair, 21, 211
inhibition, methotrexate (human), 21, 718
nucleotide levels, 21, 211
polymerase, inhibition (human), 21, 474
strand separation (mouse), 21, 739
synthesis, in cultured colon carcinoma cells (human), 21, 468
uracil incorporation, 21, 211
Dopamine
agonists (rat), 22, 281
comparison, 21, 114
3H-labeled
binding to caudate nucleus (calf), 22, 281
receptor binding (bovine), 21, 44, 52
receptor
SUBJECT INDEX 817
affinity states (porcine), 22, 298
anterior pituitary gland (porcine), 22, 290, 298
auto, y-aminobutyric acid technique (rat), 21, 114
auto-, synaptosomal tyrosine hydroxylation (rat), 21, 114
D-1, characterization (rat), 22, 281
D-1, model (rat), 22, 281
D-2 (bovine), 21, 44, 52
D-3 (bovine), 21, 44, 52
subtypes (bovine), 21, 44, 52
two affinity states (porcine), 22, 290
-sensitive adenylate cyclase
effects of sulihydryl groups (dog), 22, 595
striatal (rat), 22, 281
-sensitive adenylate cyclase complex, role of sulfhydryl groups in
coupling (dog), 22, 595
synthesis, autoreceptor control (rat), 21, 114
Dose-response curves, modification, 22, 369
“Down-regulation,” platelet alpha2-adrenergic receptors (human), 21,
36
Doxorubicin, see Adriamycin
Drug(s)
anxiolytic, quantitative structure-activity relationships, 22, 11
binding area, characterization in human serum albumin, 21, 387
design, chemotherapy, 22, 231
enzyme regulatory site-directed, 22, 231
intercalating, cellular effects (mouse), 21, 739
metabolism
in neonatal epidermis (rat), 21, 239
sexual differences (rat), 21, 744
nonsteroidal anti-inflammatory, structure-activity relationships, 22,
525
opiate, inhibition of phencycidine binding (ray), 22, 72
quatemary ammonium, interactions in Torpedo electric organ, 22,
63
resistance, in carcinoma cell line (rat), 21, 729
dThd kinase, virus-coded, 21, 432
dTMP kinase, virus-coded, 21, 432
dUMP, intracellular, effect of 5-fluorodeoxyuridine, 21, 211
dUTP, intracellular, effect of 5-fluorodeoxyuridine, 21, 211
Dynorphin binding sites, 21,266
E
Edrophomum
inhibition of acetylcholinesterase (ray), 22, 63
agonist and antagonist activity (ray), 22, 63
Effector blockade, modification of dose-response curves, 22, 369
Electron spin resonance, microsomal reduction of gentian violet (rat),
22, 239
Electrophoresis
coupled with immunochemical staining, 22, 787
cytochrome P-450, 22, 787
pulmonary cytochrome P-450 (rabbit), 22, 221
Eleptogenic property
$-alkyl-substituted -y-butyrolactones (mouse, guinea pig), 22, 431
unsubstituted y-butyrolactones (mouse, guinea pig), 22, 431
Embryo, brain, muscarinic receptors (chick), 21, 280
Enantiomer
aceclidine, binding in brain (rat), 21, 594
methotrimeprazine, differential stereoselectivity, 21, 315
Endocrine regulation of cadmium-sensitive hepatic cytochrome P-450
(rat), 22, 795
Endoplasmic reticulum
rough, epoxide hydratase activity (rat), 21, 511
smooth, epoxide hydratase activity (rat), 21, 511
Endorphin, effects in opiate addiction (rat), 22, 389
fl-Endorphinamphiphiic a- or ir-helix, 22, 657
interaction with calmodulin (bovine), 21, 86
model peptides, 22, 657
structural characteristics, 22, 657
End-plate current
amplitude, 22, 565
blockade, 21, 351
decay, 22, 565
effect of N-alkyl analogues (ray), 22, 82
neuromuscular (frog), 22, 636
time constant (frog), 21, 637
Energy-conformation calculations, 22, 667
Enkephalin
(D-A1a2, D-Leu5)-, binding sites, 21, 266
dimeric, affinity and selectivity for delta opiate receptor, 21, 558
effects in opiate addiction (rat), 22, 389
[3H}leucine
binding, effect of morphine (rat), 21, 538
binding in vitro, 21, 548
receptor, and morphine receptor, allosteric coupling in vitro, 21, 548
Enthalpy
binding, brain homogenates (rat), 22, 335
-driven binding process (rat), 22, 20
Entropy
binding, brain homogenates (rat), 22, 335
-driven binding process (rat), 22, 20
Environmental pollutants, effect on heme metabolism (rat), 21, 150
Enzyme
aromatase, catalysis, 21, 173
cardiac microsomal (fish), 21, 517
induction
phenobarbital (rat), 21, 511
trans-stilbene oxide (rat), 21, 511
liver, stereoselective metabolism of polycycic aromatic hydrocarbon
substrates (rat), 22, 182
microsomal, comparison, 22, 787
modulation, in KB cells (human), 21, 478
regulatory site-directed drugs, 22, 231
secretion
in parotid gland (rat), 21, 121
regulation (rat), 21, 121
Epidermis, neonatal, drug metabolism (rat), 21, 239
Epinephrine
inhibition of platelet adenylate cyclase (human), 22, 574
3H-labeled, alpha2-adrenergic receptors, 21, 17
pressure activity, 22, 725
Epoxide hydratase, nuclear envelope induction (rat), 21, 511
Epoxide hydrolase
activity in neonatal skin (rat), 21, 239
catalytic activity (human), 22, 190
liver microsomal (human), 22, 190
Epoxide stability, polycyclic aromatic hydrocarbons, 22, 459
Equilibrium
dialysis, cephalosporin-human serum albumin complexes, 21, 92
fluorescence, warfarin binding, 21, 100
Erythrocytes
cation fluxes (turkey), 21, 503
cyclic AMP receptors (turkey), 21, 503
free cholesterol transfer (human), 21, 694
insulin receptors, regulation by insulin and concanavalin A (frog), 22,
619
membrane, radioligand binding (frog, turkey), 21, 5
Erythroleukemia cell, cytoplasmic RNA, effect of anthracyclines, 22,
152
Erythrosine, effect on ouabain binding to digitalis receptor (rat, guinea
pig), 22, 687
Estrogen
biosynthesis, inhibition, 21, 173
receptor, translocation by SKF 525-A (rat). 21, 533
Estrogenic action, SKF 525-A (rat), 21, 533
818 SUBJECT INDEX
Ethanol, see also Alcohol
effect on dipalmitoylphosphatidylcholine, 22, 133
effect on free cholesterol transfer in erythrocytes (human), 21, 694
in vitro effects (rat, mouse), 22, 99
lipid effects, 22, 133
lipid solubiity, 22, 133
metabolism in perfused liver (rat), 21, 438
7-Ethoxycoumarin deethylase
Aroclor induction (rat), 21, 239
cytochrome P-450 inhibition, 21, 248
Ethoxyresorufin O-deethylase, activity in cardiac microsomes (fish),
21, 517
Ethylketocyclazocine binding sites, 21, 266
N-Ethylmaleimide
adenylate cyclase inhibition (dog), 22, 595
effect on pituitary dopamine receptors (porcine), 22, 298
receptor coupling (rat), 21, 570
5-Ethynyl-2’-deoxycytidine, antiherpes activity, 21, 217
Etorphine
binding to opiate receptors of caudate nucleus (sheep), 22, 648
“H-labeled
binding, 21, 548
receptor binding in vivo (rat), 21, 272
F
Fatty acids
effects on adenylate cyclase, 22, 360
effects on receptors, 22, 360
hydroperoxides, soluble guanylate cyclase activation (guinea pig), 21,
654
Flavin-containing monooxygenase, estimation, 22, 787
Flow cytometry
deoxyuridine treatment in lymphoblasts (human), 22, 166
methotrexate-treated cells, 21, 204
Fluidity, model membrane, 22, 721
Flunitrazepam
“H-labeled, kinetics of binding (rat), 21, 57
nonlinear van’t Hoff plot (rat), 22, 20
Fluorescence
enhancement assay for cellular DNA damage, 22, 145
equilibrium, warfarin binding, 21, 100
glucagon, 22, 105
quenching, DNA drug binding, 22, 486
stopped-flow, 21, 100
terbium, 22, 105
Fluoride, effect on hepatic and renal glucose-6-phosphatase activity
(rat), 22, 116
Fluorimetry
binding study, 21, 100
binding of warfarin to human serum albumin, 21, 100
5-Fluorodeoxyuridine
cytotoxicity, 21, 211
in gastrointestinal tumor (human), 21, 723
5-Fluoro-2’-deoxyuridine 5’-diphosphate, intracellular, effect of 5-fluo-
rodeoxyuridine, 21, 211
5-Fluoro-2’-deoxyuridine 5’-triphosphate, intracellular, effect of 5-fluo-
rodeoxyuridine, 21, 211
Fluorodeoxyuridylate, formation, 21, 224
5-Fluoro-5’-O-nitro-2’-deoxyuridine, cytotoxicity in L1210 cultures, 22,
760
5-Fluorouracil
DNA incorporation, 21, 211
effect on colon carcinoma cells in culture (human), 21, 468
interaction with N-(phosphonacetyl)-L-aspartate, 21, 224
-methotrexate combination, action in colon adenocarcinoma (hu-
man), 22, 771
5-Fluorouridine, effect on colon carcinoma cells in culture (human), 21,
468
Fluoxetine
inhibition of norepinephrine uptake, 21, 368
inhibition of serotonin uptake, 21, 362, 368
Fluxes
potassium, in erythrocytes (turkey), 21, 503
sodium, in erythrocytes (turkey), 21, 503
Folic acid analogue, release from hepatocytes (rat), 22, 493
Folinic acid, rescue effects in methotrexate-treated cells (human), 21,
718
Formaldehyde, cross-linking, methylmercury complexes in thymus
(calf), 22, 121
Forskolin
activation of adenylate cyclase in lymphoma cells, 22, 609
activation of cyclic AMP (rat), 22, 109
activation of lipolysis (rat), 22, 109
effect on adenylate cyclase (rat), 22, 109
effect on platelets (human), 21, 680
Fourier transform, ‘H, NMR studies on cytochrome P-450 (rabbit), 21,
701
Free-Wilsoman group contributions, theorem, 22, 725
Furan derivative, lung toxicity (rabbit), 22, 738
G
Gastric mucosa cells, interaction with histamine (guinea pig), 22, 33, 41
Gastrointestinal tumor
cytotoxicity of 5-fluorodeoxyuridine and methotrexate (human), 21,
723
thymidylate synthetase levels in cells (human), 21, 723
Genetic complementation, somatic mutants (mouse), 22, 204
Genetic mutation, single-gene (mouse), 22, 204
Genetics, adenylate cyclase (mouse), 22, 267, 274
Gentian violet, microsomal reduction (rat), 22, 239
Glioma cell, C6
calmodulin inhibitors, 22, 395
glycogen phosphorylase conversion, B to A, 22, 395
Glucagon
cation binding, 22, 105
circular dichroism, 22, 105
conformational change, 22, 105
effect on cardiac adenylate cyclase activity (rat), 22, 342
fluorescence, 22, 105
zinc binding, 22, 105
Glucocorticoids, tyrosine hydroxylase induction (mouse), 22, 421
Glucose
oxidation, oxytocin stimulation (rat), 22, 381
transport
adipocyte, effects of adenosine (rat), 22, 614
effects of oxytocin (rat), 22, 381
Glucose-6-phosphatase
activity in kidney (rat), 22, 116
activity in liver (rat), 22, 116
elevation by fluoride (rat), 22, 116
Glucuronidation
benzo[a�pyrene metabolism (rat), 22, 451
rates, 7-hydroxycoumarin (rat), 22, 509
Glutamate-stimulated calcium uptake (rat, mouse), 22, 99
y-Glutamylcysteinylglycine, analogues (hydra), 21, 629
Glutathione
alkyl halide metabolism (rat), 22, 745
receptor, peptide interaction (hydra), 21, 629
Glycine, rescue effects in methotrexate-treated cells (human), 21, 718
Glycogen phosphorylase, conversion B to A in C6 glioma cells, 22, 395
Growth inhibition, cellular (human), 21, 718
GTPbinding, regulatory protein (bovine), 21, 52
regulation, dopamine receptors (bovine), 21, 52
GTPase
hormonal stimulation, 21, 336
SUBJECT INDEX 819
low Km, stimulation by inhibitors, 21, 336
Guanine nucleotide(s)
-activated cardiac adenylate cyclase activity (rat), 22, 342
alpha2-adrenergic receptors, 21, 17
effect
on binding in purified platelet membranes (human), 21, 600
on cardiac binding sites (rat), 21, 581
on pituitary dopamine receptors (porcine), 22, 290, 298
on prostaglandin E2 receptors in adipocytes (hamster), 22, 320
interaction with cardiac receptors (rat), 21, 570
receptor
regulation (guinea pig, bovine), 21, 329
regulation (rat), 22, 532
-sensitive adenylate cyclase, effects of sulihydryl groups (dog), 22,
595
Guanosine-5’-triphosphate, effect on dopamine receptors (b*ine), 21,
52
Guanyl nucleotides, renal cortex (rat), 22, 589
Guanylate cyclase, myometrial (guinea pig), 21, 654
H
Haloethylnitrosoureas, selective cytotoxicity in carcinoma (rat), 21, 729
Halogen atoms, oxidation (rat), 22, 745
Halothane
effect on Ca2�-ATPase in cardiac sarcoplasmic reticulum (bovine),
22, 8
reductive metabolism by cytochrome P-450 (human, rabbit), 21, 710
Heart
digitalis receptor, inhibition of ouabain binding (guinea pig), 22, 687
hypertrophy, effect on muscarinic receptors (rat), 21, 589
membrane
adenylate cyclase activity (rat), 22, 342
muscarinic receptors (rat), 21, 581
microsomes
cytochrome P-450 activity (fish), 21, 517
monooxygenase activity (fish), 21, 517
mitochondrial ATPase, fluphenazine inhibition (bovine), 21, 415
muscarinic cholinergic receptor, interaction with guanine nucleotide
binding component (rat), 21, 570
muscarinic receptors (rat), 21, 581, 589
sarcoplasmic reticulum, effect of halothane (bovine), 22, 8
toxicity of anthracycline antineoplastic agents, 22, 471
Heat
inactivation, receptors in brain (rat), 22, 327
sensitivity, pituitary dopamine receptors (porcine), 22, 298
treatment, effect on dopamine receptors (bovine), 21, 52
HeLa cell, 9-fl-n-arabinofuranosyl-2-fluoroadenine inhibition (human),
21, 474
Heme
destruction by benzyl hydrodisulfide (rat), 21, 464
metabolism, effect of organometals (rat), 21, 150
oxygenase, effect of organometals (rat), 21, 150
Hemoglobin, tetrameric, subunit selectivity (rabbit), 21, 1
Hepatocyte
isolated, S-adenosylhomocysteine binding (rat), 21, 108
methotrexate release (rat), 22, 493
Hepatoxocity, norcocaine nitroxide (rat, hamster), 21, 458
Herpes simplex virus
inhibition by (E)-5-(2-bromovinyl)-2’-deoxyuridine, 21, 432
selective inhibitors, 21, 217
Heterogeneity
adenosine A, receptor binding in brain (rat, rabbit, guinea pig, calf,
human), 22, 250
binding (cat), 22, 304
species, adenosine receptor binding in brain (rat, rabbit, guinea pig,
calf, human), 22, 250
Histamine
agonist, effect on binding and biological response of gastric mucosal
cells (guinea pig), 22, 33
H, agonists, in polymorphonuclear neutrophils (human), 21, 78
H2 agonists, in polymorphonuclear neutrophils (human), 21, 78
H , antagonist
in polymorphonuclear neutrophils (human), 21, 78
long-acting (rat, guinea pig), 21, 294
H2 antagonist
effect on binding and biological reponse of gastric mucosa cells
(guinea pig), 22, 41
in polymorphonuclear neutrophils (human), 21, 78
interaction with gastric mucosal cells (guinea pig), 22, 33, 41
-mediated adenylate cyclase stimulation in myocardium (human),
21, 671
receptors
characterization in van deferens (mouse), 22, 602
in polymorphonuclear neutrophils (human), 21, 78
myocardial (human), 21, 671
surface, in promyelocytic leukemia cells (human), 22, 547
Histone, thymus
effect of methylmercury(II) (calf), 22, 121
formaldehyde cross-linking (calf), 22, 121
methylmercury complexes (calf), 22, 121
Histrionicotoxin
actions at ion channels, 21, 343
binding to electrically excitable membranes (ray), 22, 82
effect on neuromuscular transmission, 22, 565
H202, generation by hepatic cytochrome P-450 (rat), 22, 465
Hormone
inhibition, adenylate cyclase, 21, 336
stimulation, GTPase, 21, 336
Horseradish peroxidase-hydrogen peroxide oxidation of sulfite, 22, 732
Hybridization, blot
DNA (mouse), 22, 779
mRNA (mouse), 22, 779
Hybridoma, monoclonal antibodies, 21, 248
Hydra feeding receptor, 21, 629
Hydration activity, carbon dioxide, of skeletal muscle (cat), 22, 211
Hydrocarbon, polycyclic aromatic
epoxide stability, 22, 459
stereoselective metabolism (rat), 22, 182
Hydrogen peroxide
hepatic microsomal metabolism (rabbit), 22, 471
-horseradish peroxidase oxidation of sulfite, 22, 732
Hydrolase, epoxide, activity in neonatal skin (rat), 21, 239
Hydroperoxide, fatty acid, soluble guanylate cyclase activation (guinea
pig), 21, 654
Hydrophobic interaction, Ca2�-calmodulin complex with calmodulin
antagonists, 22, 403
N-Hydroxyamphetamine
effect on hepatic cytochrome P-450 (rat), 22, 465
H202 generation (rat), 22, 465
4-Hydroxy-4-androstene-3,17-dione, inhibition ofestrogen biosynthesis,
21, 173
y-Hydroxybutyrate, eleptogenic properties (mouse, guinea pig), 22, 431
7-Hydroxycoumarin, sulfation and glucuronidation rates (rat), 22, 509
6-Hydroxydopamine, cytotoxic effect, 21, 363, 368
Hydroxyl group, rOle in phenylethanolamine N-methyltransferase sub-
strate activity, 22, 127
Hydroxyl radical, production, 21, 262
Hydroxylase, tyrosine, induction by glucocorticoids (mouse), 22, 421
N-Hydroxylase
induction in liver (rat), 21, 449
modification in liver (rat), 21, 449
Hydroxylation, benzo[a]pyrene, 21, 248
N-Hydroxynorcocaine, in vitro lipid peroxidation, 22, 529
N-Hydroxyphentermine
effect on hepatic cytochrome P-450 (rat), 22, 465
820 SUBJECT INDEX
dihydrofolate reductase (human), 21, 231
N-hydroxyphentermine-continued
H2O2 generation (rat), 22, 465
phentermine N-oxidation to (rabbit), 22, 235
8-Hydroxyquinoline, antimalarial activity, 22, 140
Hyperthyroidism, effect on cardiac muscarmnic receptors (rat), 21, 589
Hypertrophy, cardiac, effect on muscarmnic receptors (rat), 21, 589
Hypnotics, interaction with benzodiazepine receptors, 21, 320
Hypoglycemia, sulfonylureas, Ca2� ionophoretic activity (mouse), 22,
715
Hypothalamus
catecholamine uptake system (rat), 21, 374
synaptosomal protein carboxymethyltransferase (rat), 21, 181
Hypothermia, effect on muscannic agonist binding (rat), 21, 594
Hypothyroidism
effect on adipocytes (rat), 22, 109
effect on cardiac muscarinic receptors (rat), 21, 589
Hypoxia, leukemia cells, synergistic toxicity of misonidazole and sulfi-
docyclophosphamide (mouse), 22, 175
Ileum
I
binding of f�-endorphin, models (guinea pig), 22, 657
field-stimulated (guinea pig), 21, 259
Imidazolidines, X-ray structure, 21, 400
Immunochemical quantitation, flavin-containing monooxygenase, 22,
787
Immunochemical staining, coupled with electrophoresis, 22, 787
Immunochemistry
cytochrome P-450 (rat), 21, 744, 753
liver microsomal epoxide hydrolase (human), 22, 190
Immunodiffusion, radial, measurement of cytochrome P-450 concentra-
tion (rat), 21, 753
Immunoprecipitation, monoamine oxidase B, 22, 500
Immunoreactivity, antinucleoside (mouse), 21, 739
Imprinting, neonatal, and hepatic cytochrome P-450 (rat), 21, 744
Inactivation
heat, receptors in brain (rat), 22, 327
suicide
cytochrome P-450 (rat), 21, 166
hepatic arylhydroxamic acid N,O-acyltransferase (hamster), 21,
159
Inelastic electron tunneling spectroscopy, interaction of acetylcholine
and fl-methyl acetylcholine with alumina surface, 22, 678
Inflammation, role of neutrophils (rat), 21, 688
Inhibition
acetylcholinesterase (ray), 22, 63
S-adenosyl-L-methionine biosynthesis (rat), 22, 752
adenylate cyclase
by �:i+ (mouse), 22, 274
by Sc”� (mouse), 22, 274
in neuroblastoma cells, 21, 483
in renal cortex (rat), 22, 589
opiate, 21, 483
receptor-mediated (rat), 21, 570
[“H]batrachotoxinin A 20-a-benzoate binding, 22, 627
DNA, methotrexate (human), 21, 718
estrogen biosynthesis, 21, 173
human lymphoid, by antifolate BW3O1U, 22, 766
insulin secretion, alpha2-adrenergic receptor (rat), 21, 648
leukemia L1210 cells, by acndine derivatives (mouse), 22, 486
light-enhanced, ouabain binding to digitalis receptor (rat, guinea pig),
22, 687
liver cytochrome P-450 (rat), 21, 464
magnesium-dependent, heart soluble mitochondrial ATPase (bo-
vine), 21, 415
magnesium transport (mouse), 22, 274
metabolism, inhibition by antifolate BW3O1U (mouse), 22, 766
[3H]phencyclidine interactions with acetylcholine receptor channel
(ray), 22, 72
phenyl-N-methyltransferase, 22, 725
Plasmodium falciparum growth, by selected aromatic chelators, 22,
140
platelet adenylate cyclase (human), 21, 609; 22, 574
platelet cyclic AMP generation (human), 21, 680
prostaglandin synthesis (toad), 21, 142
protein kinase, 22, 408
protein synthesis in brain and liver (rat), 22, 706
quinone, hepatic (rat), 22, 451
RNA polyadenylation, 22, 517
skeletal muscle carbonic anhydrase (cat), 22, 211
synaptosomal protein carboxymethyltransferase (calf, rat), 21, 181
Inhibitor
adipocyte adenylate cyclase, 21, 336
calmodulin, in C6 glioma cells, 22, 395
microtubular, effect on Ca2�-transport ATPase, 22, 413
norepinephrine uptake, 21, 380
tricyclic, dopamine, in striatum and hypothalamus (rat), 21, 374
Insulin
binding sites, in erythrocytes (frog), 22, 619
-like activity of oxytocin (rat), 22, 381
receptors
adipocyte, effects of adenosine (rat), 22, 614
down-regulation (frog), 22, 619
erythrocyte, regulation by insulin and concanavalin A (frog), 22,
619
regulation of insulin receptors in erythrocytes (frog), 22, 619
resistance, oxytocin and (rat), 22, 381
secretion, inhibition by alpha2-adrenergic receptors (rat), 21, 648
sensitivity, modulation by adenosine (rat), 22, 614
Intercalating drugs, cellular effects (mouse), 21, 739
5-Iodo-2’-deoxycytidine, antiherpes activity, 21, 217
(E)-5-(2-Iodovinyl)-2’-deoxycytidine, antiviral and antimetabolic prop-
erties, 21, 217
Ion
aziridinium, inhibition of norepinephrine uptake, 21, 380
channel
acetylcholine receptor, meproadifen reaction with (frog), 22, 636
activation, 22, 565
blockade, 21, 351; 22, 565
muscle membranes, 21, 351
neuroblastoma variants, 22, 196
nicotinic acetylcholine receptor, 21, 351
nicotinic acetylcholine receptor (ray), 22, 82
receptor (frog), 21, 637
nickel, modulation (rat), 22, 335
benzodiazepine receptor (mouse), 21, 618
role in adenylate cyclase inhibition (rat), 22, 589
transport, effect of anticonvulsant drugs, 22, 627
Ionophore
-a-aminobutyric acid complex, 21, 320
Ca2F
effect on cyclic AMP, 22, 310
hypoglycemic sulfonylureas (mouse), 22, 715
Isomer, optical, methotrimeprazine, 21, 315
Isoproterenol, effect on cardiac adenylate cyclase activity (rat), 22,342
Isosafrole
induction of cytochrome P-450 subpopulations (rat), 21, 527
induction of cytochrome P,-450 (mouse), 22, 779
Isozyme
cytochrome P-450, catalytic activity (rabbit), 22, 738
mammalian ATP:L-methionine S-adenosyltransferase, differences in
active-site region (rat), 22, 752
purified microsomal, interaction with acet.anilide (rabbit), 21, 701
K
K� depolarization (mouse), 22, 715
KB cell
SUBJECT INDEX 821
effect on adenylate cyclase (mouse), 22, 267
methotrexate-resistant (human), 21, 231, 478
Ketanserin
functional role (rat), 21, 301
3H-labeledbinding properties (rat), 21, 301
selectivity (rat), 21, 301
Kidney
adenylate cyclase-coupled alpha2-adrenergic receptors (rat), 22, 589
effect of adrenalectomy (rat), 22, 116
glucose-6-phosphatase activity (rat), 22, 116
microsomes, cysteine S-conjugate N-acetyltransferase (rat), 21, 444
phenacetin toxicity, 22, 479
Kinase
protein
activation in parotid gland (rat), 21, 121
cyclic AMP, 21, 121
inhibition, 22, 408
thymidylate, virus-coded, 21, 432
Kinetics
N,O-acyltransferase inactivation (hamster), 21, 159
aryihydroxamic acid, suicide inactivation (hamster), 21, 159
binding
association and dissociation (rat), 21, 57
warfarin to human serum albumin, 21, 100
benzo[a]pyrene metabolism (rat), 22, 451
[3H]flunitrazepam binding (rat), 21, 57
opiate receptor binding (sheep), 22, 648
Km, low, GTPase, 21, 336
Lj�3+ inhibition of adenylate cyclase (mouse), 22, 274
Labeling, selective, serotonin-2 receptors (rat), 21, 301
Lecithin, egg vesicles, 21, 694
Lergotrile, effect on dopamine synthesis (rat), 21, 114
Leucine enkephalin, ‘H-labeled
binding in vitro, 21, 548
effect of morphine on binding (rat), 21, 538
Leukemia
cell, hypoxic, synergistic toxicity of misonidazole and sulfidocyclo-
phosphamide (mouse), 22, 175
L1210 cells
cytotoxicity of 5-fluoro-5’-O-nitro-2’-deoxyuridine, 22, 760
inhibition by acridine derivatives (mouse), 22, 486
promyelocytic cell line HL-60 (human), 22, 547
Levitimide, inhibition of binding in heart (rat), 21, 581
Levomepromazine, ring sulfoxidation, 21, 409
Ligand
adrenergic
liposolubiity in membranes (rat), 22, 5
n-octanol:water (rat), 22, 5
delta- and mu-, chronic treatment, cross-tolerance, 22, 1
3H-labeled, binding in caudate membrane (bovine), 21, 52
selective, for serotonin2 (rat), 21, 301
Lipid
acidic, cerebroside sulfate, 21, 492
effects of ethanol, 22, 133
effect on adenylate cyclase activity, 21, 492
effect on opiate inhibition, 21, 492
effect on opiates, 21, 492
incorporation in neuroblastoma N18TG2 cells, 21, 492
in vitro peroxidation, 22, 529
synthesis, adipocyte, effects of adenosine (rat), 22, 614
thermotropic properties, 22, 133
transition cooperativity, 22, 133
vesicles, free cholesterol transfer (human), 21, 694
Lipogenesis, oxytocin stimulation (rat), 22, 381
Lipolysis, forskolin activation in adipocytes (rat), 22, 109
Lipophiic chelator, antimalarial activity, 22, 140
Lipophiic-hydrophiic balance, antileukemic activity of acridine deny-
atives, 22, 486
Lipoproteins
free cholesterol transfer (human), 21, 694
high-density, free cholesterol transfer (human), 21, 694
low-density, free cholesterol transfer (human), 21, 694
Liposolubiity, adrenergic ligand in membranes (rat), 22, 5
Lipoxygenase
metabolism of arachidonic acid by neutrophils (rat), 21, 688
pathway, guanylate cyclase activation (guinea pig), 21, 654
Liver
N-acetyltransferase multiplicity (hamster), 21, 159
ATP concentration, effect of morphine (rat), 22, 706
cytochrome P-450
cadmium-sensitive (rat), 22, 795
inactivation (rat), 21, 166
induction with pregnenolone-16a-carbonitrile (rat), 21, 753
inhibition by benzyl hydrodisulflde (rat), 21, 464
neonatal imprinting and (rat), 21, 744
turnover (rat), 21, 744
subpopulations, induction by phenobarbital, /3-naphthoflavone,
and isosafrole (rat), 21, 527
cytochrome P,-450, mRNA (mouse), 22, 779
effect of adrenalectomy (rat), 22, 116
enzymes, stereoselective metabolism of polycyclic aromatic hydro-
carbon substrates (rat), 22, 182
glucose-6-phosphatase activity (rat), 22, 116
glucuronidation rates, 7-hydroxycoumarin (rat), 22, 509
microsomes
arylamide N-hydroxylase (rat), 21, 449
benzo[a]pyrene metabolism (rat), 22, 451
drug metabolism (rabbit), 22, 471
epoxide hydrolase (human), 22, 190
‘H Fourier transform NMR studies (rabbit), 21, 701
H2O2 generation (rat), 22, 465
inhibition of oxidative drug metabolism (rabbit), 22, 471
metabolism of propyl halides (rat), 22, 745
mixed-function oxidase (rat), 21, 150
N-oxidation of phentermine (rabbit), 22, 235
perfused, ethanol metabolism (rat), 21, 438
plasma membrane, S-adenosylhomocysteine binding (rat), 21, 108
protein synthesis inhibition by morphine (rat), 22, 706
reconstituted cytochrome P-450 (rabbit), 22, 235
sulfation rates, 7-hydroxycoumarin (rat), 22, 509
toxicity, norcocaine nitroxide (rat, hamster), 21, 458
Lung
cytochrome P-450
isozymes, catalytic activity (rabbit), 22, 738
3-methylcholanthrene induction (rabbit), 22, 221
toxicity of 4-ipomeanol (rabbit), 22, 738
Lymphoblast, cultured, deoxyuridine metabolism (human), 22, 166
Lymphoid, inhibition by antifolate BW3O1U (human), 22, 766
Lymphoma cell
549, adenylate cyclase phenotypes (mouse), 22, 204
variant, adenylate cyclase activation, 22, 609
wild-type, adenylate cyclase activation, 22, 609
Lysosomatic amines, erythrocyte (frog), 22, 619
M
Magnesium
alpha2-adrenergic receptors, 21, 17
-dependent inhibition, heart soluble mitochondrial ATPase (bovine),
21, 415
regulation
of adenylate cyclase (mouse), 22, 267, 274
of beta-adrenergic receptor (mouse), 22, 267, 274
transport, inhibition (mouse), 22, 274
Malaria, human, treatment with lipophiic chelators, 22, 140
Manganese
822 SUBJECT INDEX
analogues, 21, 231
Manganese-continued
effect on opiate binding (rat), 21, 564
effect on receptor binding (mouse), 22, 267
Marcellomycin, effect on cytoplasmic RNA in erythroleukemia cells,
22, 152
Mass spectrometry, �2Cf plasma desorption (rat), 21, 688
Membrane
adipocyte, adrenergic ligand liposolubiity in (rat), 22, 5
-bound benzodiazepine receptors, kinetics of binding (rat), 21, 57
brain, opiate binding (rat), 21, 564
cardiac
adenylate cyclase activity (rat), 22, 342
muscarinic receptors (rat), 21, 581
caudate, “H-ligand binding sites (bovine), 21, 44, 52
electrically excitable, interaction with N-alkyl analogues (ray), 22,82
erythrocyte, free cholesterol transfer (human), 21, 694
islet cell, adenylate cyclase (rat), 21, 648
lipid
effects on adenylate cyclase, 22, 360
effects on receptors, 22, 360
liver plasma, S-adenosylhomocysteine binding (rat), 21, 108
model, fluidity, 22, 721
muscle, voltage-sensitive ion channels, 21, 351
nerve, sodium channel binding sites, 21, 343
plasma, Ca2ttransport ATPase (human), 22, 413
platelet, purified, binding (human), 21, 600
synaptosomal
binding sites (rat), 21, 57
cholinergic muscarinic receptor (cat), 22, 304
Meproadifen, effect on acetylcholine receptor (frog), 22, 636
Mesencephalic cell, primary culture, substance P derivative binding
(mouse), 22, 48
Metabolic activation
antineoplastic agents (rabbit), 22, 471
phenacetin metabolites, 22, 479
Metabolic-intermediate complexes, cytochrome P-450 (rat), 21, 527
Metabolism
N-alkyl compounds, 21, 133
anthracycline antineoplastic agents (rabbit), 22, 471
benzo[a]pyrene (fish), 21, 517
benzo[a�pyrene, kinetic determinants (rat), 22, 451
deoxyuridine, in lymphoblasts (human), 22, 166
drugs
in neonatal epidermis (rat), 21, 239
sexual differences (rat), 21, 744
ethanol, in perfused liver (rat), 21, 438
heme, effect of organometals (rat), 21, 150
inhibition, by antifolate BW3O1U (mouse), 22, 766
methotrexate, cellular (human), 21, 718
peroxidase, 21, 133
reductive, halothane, by cytochrome P-450 (human, rabbit), 21, 710
stereoselective, chrysene 1,2-dihydriols (rat), 22, 182
Metabolite
active, chioramphenicol (rat), 21, 166
arachidonic acid, stimulation of neuroblastoma adenylate cyclase, 21,
664
chlorpromazine, ring sulfoxidation, 21, 409
cocaine, hepatotoxicity (rat, hamster), 21, 458
methotrimeprazine, ring sulfoxidation, 21, 409
phenacetin, activation, 22, 479
sulfoxide, effect on neuroleptic potency, 21, 409
Methiodide, aceclidine, binding in brain (rat), 21, 594
Methionine adenosyltransferase, tumor and normal, substrate specific-
ities (rat), 22, 752
L-Methionine, analogues, substrate and inhibitory properties (rat), 22,
752
Methotrexate
catecholamine-induced release from hepatocytes (rat), 22, 493
cellular effects, 21, 204
cytotoxicity (human), 21, 718
in gastrointestinal tumor, 21, 723
effect on dihydrofolate reductase activity (human), 21, 478
5-fluorouracil combination, action in colon adenocarcinoma (human),
22, 771lymphoblastoid resistance (human), 22, 766
metabolic inhibition in mouse cell lines, 22, 766
metabolism, cellular (human), 21, 718
polyglutamates, accumulation in cells (human), 21, 718
-resistant KB cells (human), 21, 231, 478
-treated cells, rescue agents (human), 21, 718
Methotrimeprazine
enantiomers, differential stereoselectivity, 21, 315
optical isomers, 21, 315
ring sulfoxidation, 21, 409
fl-Methyl acetylcholine, interaction with alumina surface, 22, 678
3-Methylcholanthrene, induction
cytochrome P,-450 (mouse), 22, 779
liver microsomes, benzo[a]pyrene metabolism (rat), 22, 451
pulmonary cytochrome P-450 (rabbit), 22, 221
Methylmercury II, effect on histones (calf), 22, 121
Methyltransferase, phospholipid, in liver plasma membranes (rat), 21,
108
Microcalorimetry, cephalosporin-human serum albumin complexes, 21,
92
Microsome
cardiac, cytochrome P-450 and monooxygenase activity (fish), 21,
517
enzymes, comparison, 22, 787hepatic
arylamide N-hydroxylase (rat), 21, 449
benzo[a}pyrene metabolism (rat), 22, 451
drug metabolism (rabbit), 22, 471
epoxide hydrolase (human), 22, 190
‘H Fourier transform NMR studies (rabbit), 21, 701
H2O2 generation (rat), 22, 465
inhibition of oxidative drug metabolism (rabbit), 22, 471
metabolism of propyl halides (rat), 22, 745
3-methylcholanthrene-induced (rat), 22, 451
reduction of gentian violet (rat), 22, 239
renal, cysteine S-conjugate N-acetyltransferase (rat), 21, 444
Misonidazole, cytotoxicity, synergism with sulfidocyclophosphamide
(mouse ), 22, 175
Mitochondria, heart ATPase, fluphenazine inhibition (bovine), 21, 415
Mitoxantrone, hepatic microsomal metabolism (rabbit), 22, 471
Model membrane, fluidity, 22, 721
Molecular conformation, solid-state, 21, 409
Molecular orbital calculations, polycycic aromatic hydrocarbon epox-
ide stability, 22, 459
Molecular shape analysis, 1-(X-phenyl)-3,3-dialkyltriazenes, 21, 187
Molecular structure, 3-carbomethoxy rifamycin 5, 21, 394
Monoamine oxidase
Bimmunoprecipitation, 22, 500
monoclonal antibody to, 22, 500
pargyline labeling, 22, 500
platelet (human), 22, 500
separation of A and B, 22, 500
Monoclonal antibody
distinction of monoamine oxidase A and B, 22, 500
hybridoma, 21, 248
to cytochrome P-4SOLM2 and P-450LM4, 21, 248
to monoamine oxidase B (human), 22, 500
Monohydroxyaminotetralins
enantiomeric, effect on dopamine binding (rat), 22, 281
racemic, effect on dopamine binding (rat), 22, 281
SUBJECT INDEX 823
Monooxygenase
activity, in cardiac microsomes (fish), 21, 517
-like activity, of tetrameric hemoglobin (rabbit), 21, 1
reconstituted system (rat), 21, 166
Morphine
effect on ATP concentration in brain and liver (rat), 22, 706
effect on binding of [3H]leucine enkephalin (rat), 21, 538
effect on blood pH, Po2, and Pco2 (rat), 22, 706
effect on calmodulin activity in brain (rat), 22, 389
effect on protein synthesis in brain and liver (rat), 22, 706
receptors, and enkephalin receptors, allosteric coupling in vitro, 21,
548
Morphology, cellular transformation (mouse), 21, 739
Mucosa, fundic, cells, interaction with histamine (guinea pig), 22, 33,
41
Muscarinic receptor
binding, aceclidine and its methiodide (rat), 21, 594
central (cat), 22, 304
cholinergic
activation of phosphodiesterase, 22, 310
effect of phencyclidine (frog), 21, 637
synaptosomal membrane (cat), 22, 304
Muscle
cloned cell line, BC3H-1 (mouse), 22, 258
denervated (frog), 22, 636
membrane, voltage-sensitive ion channels, 21, 351
skeletal
action potential (frog, ray), 22, 82
carbonic anhydrase, carbon dioxide hydration activity (cat), 22,
211
twitcheffect of meproadifen (frog), 22, 636
effect of N-alkyl analogues of amantadine (frog), 22, 82
Mutagenic effect, sodium channels, 22, 196
Mutagenicity, Ames test, 21, 187
Mutant, somatic, genetic complementation (mouse), 22, 204
Mutation, single-gene (mouse), 22, 204
Myocardium, histamine-mediated adenylate cyclase stimulation (hu-
man), 21, 671
Myometrium
carbachol, phospholipase A2 activation (guinea pig), 21, 654
guanylate cyclase (guinea pig), 21, 654
N
NADH dehydrogenase, hepatic microsomal (rabbit), 22, 471
NADPH-cytochrome P-450 reductase, hepatic microsomal (rabbit), 22, 471
oxidation, hepatic microsomal (rabbit), 22, 471
Na,K-ATPase
ADP-sensitive, phosphoenzyme-rich (electric eel), 22, 693
conversion of ADP-sensitive to K�-sensitive phosphorylated forms
(electric eel), 22, 693
oligomycin interaction (electric eel), 22, 693
phosphorylated intermediate
ADP-sensitive (electric eel), 22, 693
interaction with ouabain (electric eel), 22, 700
Naloxone
3H-labeled, binding in brain (rat), 22, 349
prevention of acute effect of morphine on protein synthesis in brain
and liver (rat), 22, 706
Naphthalenesulfonamide derivatives
effect on Ca2�-calinodulin complex, 22, 403
phosphorylation modulation, 22,408
$-Naphthoflavone, induction of cytochrome P-450 subpopulations
(rat), 21, 527
Narcotic analgesia, 21, 548
Neonate, imprinting, and hepatic cytochrome P-450 (rat), 21, 744
Nephrotoxicity, phenacetin-induced, 22, 479
Nerve membrane, sodium channel binding sites, 21, 343
Neuroblastoma cells
cultured, adenylate cyclase, 21, 664
x glioma hybrid
adenylate cyclase activity, 22, 360
alpha2-adrenergic receptors, 21, 17
x glioma NG1O8-15 hybrid
alpha2-adrenergic receptors, 21, 17
opiate inhibition, 21, 483
opiate receptor activity, 22, 1
N18TG2
opiate inhibition, 21, 483
potentiation of opiate action, 21, 492
serotonin uptake, 21, 362
tyrosine hydroxylase induction (mouse), 22, 421
variant clones, characterization, 22, 196
Neuroleptic potency, effect of ring sulfoxidation, 21, 409
Neuroleptics, effect on glycogen phosphorylase, 22, 395
Neuromuscular blockade, pumiliotoxin-C, 22, 565
Neuromuscular junction, desensitization (frog), 22, 636
Neuromuscular transmission, effect of meproadifen (frog), 22, 636
Neuronal cell, culture (mouse), 22, 48
Neutrophil
formation of diarachidonyl diglyceride (rat), 21, 688
functions (human), 21, 78
peripheral (human), 22, 547
polymorphonuclear, histamine receptors (human), 21, 78
Nickel ion, modulation (rat), 22, 335
Nicotine, binding in brain (mouse), 22, 554
Nicotinic acid, prostaglandins, 21, 336
Nicotimc antagonists, binding, 22, 565
Nicotinic receptor
binding in brain (mouse), 22, 554
effect of phencyclidine (frog), 21, 637
5-Nitro-2’-deoxycytidine, antiherpes activity, 21, 217
Nitrogen
bifunctional mustards, carcinoma cell line resistance (rat), 21, 729
oxidation, cytochrome P-450-dependent (rabbit), 22, 235
Nitrosoureas, selective cytotoxicity in carcinoma (rat), 21, 729
Nonlinear least-squares curve fitting, insulin binding study (frog), 22,
619
Norcocaine nitroxide
induced hepatotoxicity (rat, hamster), 21, 458
in vitro lipid peroxidation, 22, 529
Norepinephrine
inhibition of serotonin uptake, 21, 362
uptake
in pheochromocytoma cells, 21, 368
inhibition by xylamine, 21, 380
Norfenfluramine, conformationally defined analogues, 22, 127
Nuclear envelope, epoxide hydratase, inducibility (rat), 21, 511
Nuclear magnetic resonance
cephalosporin-human serum albumin complexes, 21, 92
‘H3-carbomethoxy rifamycin 5, 21, 394
Fourier transform, cytochrome P-450 (rabbit), 21, 701
Nuclear structure, effect of nitrosoureas (rat), 21, 729
Nucleoside
adenine, effects on RNA synthesis, 22, 517
molecular associations with Adriamycin, 22, 158
Nucleotide(s)
guanine-activated cardiac adenylate cyclase activity (rat), 22, 342
alpha2-adrenergic receptors, 21, 17
effect on cardiac binding sites (rat), 21, 581
effect on pituitary dopamine receptors (porcine), 22, 290, 298
effect on prostaglandin E2 receptors in adipocytes (hamster), 22,
320
824 SUBJECT INDEX
Nucleotide-continued
guanine-continued
interaction with cardiac receptors (rat), 21, 570
receptor regulation (guinea pig, bovine), 21, 329
receptor regulation (rat), 22, 532
guanyl, renal cortex (rat), 22, 589
levels in cells treated with 5-fluorodeoxyuridine, 21, 211
molecular association with Adriamycin, 22, 158
pyrimidine, biosynthesis, 21, 224
Nucleus
histones, effect of methylmercury (II) (calf), 22, 121
thymus, formaldehyde cross-linking (calf), 22, 121
0
Oligomycin, inhibition of ADP-sensitive K�-sensitive change (electric
eel), 22, 693
Opiate
action, potentiation in neuroblastoma N18TG2 cells, 21, 492
addiction, effects on calmodulin activity (rat), 22, 389
agonist
binding model (rat), 22, 349
potency and efficacy, 21, 483
alkaloids, in brain (rat), 21, 564
analgesia (rat), 21, 272
antagonist, binding model (rat), 22, 349
chronic treatment, effect on opiate receptor activity, 22, 1
delta-, receptor site, 21, 266
drugs, inhibition of phencycidine binding (ray), 22, 72
effect, chronic, 21, 483
inhibition
adenylate cyclase activity, 21, 483
adenylate cyclase, Na� and GTP effect, 21, 483
interaction with phencyclidine (ray), 22, 72
kappa-, receptor site, 21, 266
mu-, receptor site, 21, 266
receptor
binding, 21, 483, 492
binding in brain (rat), 21, 564
binding models (rat), 21, 272
binding sites, 21, 266
caudate nucleus, etorphine binding (sheep), 22, 648
delta, 21, 558
desensitization, 22, 1
down regulation, time course, 22, 1
effect relationship (rat), 21, 272
in neuroblastoma x glioma NG1O8-15 hybrid cells, 22, 1
in vivo binding (rat), 21, 272
membrane lipid effects, 22, 360
multiple (rat), 21, 564
multiple, coupling in vitro, 21, 548
multiple, in brain (rat), 21, 538
multiple sites, 21, 266
various brain areas (rat), 22, 389
sigma receptor site, 21, 266
tetrapeptide, conformational-energy studies, 22, 667
Optical isomer, methotrimeprazine, 21, 315
Opioid
peptides
binding in brain (rat), 21, 564
interaction with /3-endorphin (bovine), 21, 86
receptor
allosteric effects, 21, 548
allosteric effects (rat), 21, 538
binding, two-state model (rat), 22, 349
Organometals, effect on heme metabolism (rat), 21, 150
Ouabain
binding to digitalis receptor (rat, guinea pig), 22, 687
interaction with phosphorylated intermediate ofNa,K-ATPase (elec-
tric eel), 22, 700
Overlap, with fused ring opiates, 22, 667
Oxidase
cytochrome P-450, N-oxidation of phentermine (rabbit), 22, 235
mixed-functionbenzo[a]pyrene oxygenation, 21, 248
hepatic (rat), 21, 150
in neonatal skin (rat), 21, 239
monamine
B, immunoprecipitation, 22, 500
B, monoclonal antibody to, 22, 500
B, pargyline labeling, 22, 500
platelet (human), 22, 500
separation of A and B, 22, 500
Oxidation
horseradish peroxidase-hydrogen peroxide, of sulfite, 22, 732
NADPH, hepatic microsomal (rabbit), 22, 471
nitrogen, cytochrome P-450-dependent (rabbit), 22, 235
phentermine, cytochrome P-450-dependent (rabbit), 22, 235
N-Oxidation, phentermine, by cytochrome P-450 oxidase system (rab-
bit), 22, 235
Oxine derivatives, antimalarial activity, 22, 140
Oxotremorine
binding in brain (rat), 21, 594
3H-labeled, binding in heart (rat), 21, 581, 589
Oxygenase, heme, effect of organometals (rat), 21, 150
Oxytocin
action in adipocytes (rat), 22, 381
adipocyte receptors (rat), 22, 381
analogues, action in adipocytes (rat), 22, 381
glucose transport (rat), 22, 381
insulin-like activity (rat), 22, 381
insulin resistance (rat), 22, 381
stimulation of glucose oxidation (rat), 22, 381
stimulation of lipogenesis (rat), 22, 381
stimulation of pyruvate dehydrogenase (rat), 22, 381
P
Pancreas islets
calcium transport (mouse), 22, 715
cyclic AMP generation (rat), 21, 648
Parinaric acid, absorbance in lipid, 22, 133
Pargyline, labeling of monoamine oxidase B, 22, 500
Parotid cell, alpha,-adrenergic stimulation (rat), 21, 128
Parotid gland
phosphatidylinositol-phosphatidic acid turnover (rat), 21, 128
protein kinase activation (rat), 21, 121
Partition coefficient, adrenergic ligand liposolubiity (rat), 22, 5
Peptide
interaction of glutathione receptor of hydra, 21, 629
opioid
binding in brain (rat), 21, 564
interaction with calmodulin (bovine), 21, 86
Permeability, potassium (frog), 21, 637
Pergolide, effect on dopamine synthesis (rat), 21, 114
Peroxidase metabolism, 21, 133
Peroxidation, lipid, in vitro, 22, 529
Pharmacological shift ratio, definition, 22, 580
Pharmacophore, benzodiazepine, 22, 11
Phase transitions, dipalmitoylphosphatidylcholine, 22, 133
Phenacetin metabolites, activation, 22, 479
Phencycidine
analogues (frog), 21, 637
binding to acetylcholine receptor (ray), 22, 72
behavioral effects (frog), 21, 637
binding to channel sites (ray), 22, 72
3H-labeled
binding to channel sites (ray), 22, 63
interaction with nicrotinic acetylcholine receptor channel (ray),
SUBJECT INDEX 825
22, 72
potassium permeability (frog), 21,637
Phenobarbitalenzyme induction (rat), 21, 511
induction of cytochrome P-450 subpopulations (rat), 21, 527
induction of hepatic cytochrome P450 (rat), 21, 753
Phenotype, adenylate cyclase, in S49 lymphoma cells (mouse), 22, 204
Phenoxybenzamine, dopamine receptor alkylation (bovine), 21, 44
Phentermine
oxidation, cytochrome P-450-dependent (rabbit), 22, 235
N-oxidation, by cytochrome P-450 oxidase system (rabbit), 22, 235
1-(X-Phenyl)-3,3-dialkyltriazenes
Ames test, 21, 187
antitumor activity, 21, 187
Phenylethanolamine, trifluoromethyl-substituted, 22, 127
Phenylethanolamine N-methyltransferase
inhibition, 22, 127
substrates, 22, 127
Phenylethylamine
conformationally defined analogues, 22, 127
pharmacological activity, 22, 725
Phenylisopropyladenosine, effects on glucose transport (rat), 22, 614
Phenyl-N-methyltransferase
inhibition, 22, 725
substrate activity, 22, 725
N-Phenylnaphthylamine, in study of membrane fluidity, 22, 721
Phenyltriazenes, molecular shape analysis, 21, 187
Pheochromocytoma cellsnorepinephrine uptake, 21, 368
serotonin uptake, 21, 368
Phosphatidic acid, turnover in parotid cells (rat), 21, 128
Phosphatidylinositol, turnover in parotid cells (rat), 21, 128
Phosphodiesterase
Ca2�-dependent activation, 22, 310
muscarinic cholinergic receptor-mediated activation, 22, 310
Phospholipid
binding of 1-chloro-2,2,2-trifluoroethyl radical (human, rabbit), 21,
710
methyltransferase, in liver plasma membranes (rat), 21, 108
vesicles, egg lecithin (human), 21, 694
N-(Phosphonacetyl)-L-aspartate, interaction with 5-fluorouracil, 21,
224
5-Phosphoribosyl-1-pyrophosphate, effect of methotrexate-5-fluorour-
acil on concentrations in colon xenografts (human), 22, 771
Phosphorylase, glycogen, conversion B to A in C6 glioma cells, 22, 395
Phosphorylated intermediate
ADP-sensitive, in Na,K-ATPase preparation (electric eel), 22, 693
Na,K-ATPase, interaction with ouabain (electric eel), 22, 700
Phosphorylation
Ca24-calmodulin-dependent, 22, 408
protein, in human platelets, 21, 422
Photoaffinity labeling
erythrocytes (turkey), 21, 503
sparing of fI-carboline binding (mouse), 21, 618
Picrotoxin binding sites, in brain (rat), 22, 327
Picrotoxinin, structure-activity relationships (mouse, guinea pig), 22,
444
Piocarpine binding in heart (rat), 21, 581
Pituitary gland
anterior
dopamine receptor (porcine), 22, 290, 298
prolactin secretion (porcine), 22, 298
effects on hepatic cytochrome P-450 (rat), 22, 795
Plasma desorption, 252Cf, mass spectrometry (rat), 21, 688
Plasma membrane, Ca2�-transport ATPase (human), 22, 413
Plasmodium falciparum, inhibition by selected aromatic chelators, 22,
140
Plasticity, synaptic, 21, 280
Platelet(s)
adenylate cyclase (human), 22, 574
alpha2-adrenergic receptors (human), 21, 36, 609; 22, 574
calcium mobilization, effect of trifluoperazine (human), 21, 422
inhibition of aggregation (human), 21, 680
membranes, purified, binding (human), 21, 600
monoamine oxidase, monoclonal antibody to (human), 22, 500
protein phosphorylation, effect of trifluoperazine (human), 21, 422
secretion and aggregation, effect of trifluoperazine (human), 21, 422
storage of biogenic amines (human), 22, 94
Pollutants, environmental, effect on heme metabolism (rat), 21, 150
Polyadenylation, RNA, inhibition, 22, 517
Poly(A)�-RNA, synthesis, 22, 152
Polycyclic aromatic hydrocarbons
carcinogenic, epoxide stability, 22, 459
stereoselective metabolism (rat), 22, 182
Polyglutamates, methotrexate, accumulation in cells (human), 21, 718
PolymeraseDNA, inhibition (human), 21, 474
DNA-dependent RNA, inhibition by rifamycin, 21, 394
Polysome
brain, effect of morphine (rat), 22, 706
liver, effect of morphine (rat), 22, 706
Potassiumfluxes, in erythrocytes (turkey), 21, 503
permeability (frog), 21, 637
-stimulated calcium uptake (rat, mouse), 22, 99
Potentiation, opiate action, in neuroblastoma N18TG2 cells, 21, 492
Prazosin, 3H-labeled
alpha,-adrenergic receptor (mouse), 22, 258
binding in renal cortex (rat), 22, 532
Pregnenolone-16a-carbonitrile
effect on hepatic tyrosine aminotransferase (rat), 21, 753
induction of hepatic cytochrome P-450 (rat), 21, 753
Prolactin secretion
anterior pituitary gland (porcine), 22, 298
control (porcine), 22, 290
n-Propylapomorphine, 3H-labeled, binding in pituitary (porcine), 22,
290, 298
N-n-Propylapomorphine, effect on dopamine synthesis (rat), 21, 114
5-Propyl-2’-deoxycytidine, antiherpes activity, 21, 217
Propyl $-carboline-3-carboxylate, 3H-labeled, binding (mouse), 21, 618
Propyl halides, metabolism in liver (rat), 22, 745
N-n-Propyl-3-(hydroxyphenyl)-piperidine, effect on dopamine synthe-
sis (rat), 21, 114
3,3’-[(Propylimino)di-2,1-ethanediyl]bis[phenol], effect on dopamine
synthesis (rat), 21, 114
Prostacyclin, stimulation of cyclic AMP in cultured neuroblastoma, 21,
664
Prostaglandin
activation of platelet adenylate cyclase (human), 21, 680
biosynthesis, N-alkylation during, 21, 133
E, immunoreactiye (toad), 21, 142
E2
binding regulation (hamster), 22, 320
receptor in adipocytes (hamster), 22, 320
effect on cultured thyroid cells (porcine), 21, 66
inhibition of platelet aggregation (human), 21, 680
nictotinic acid, 21, 336
receptors
in promyelocytic leukemia cells (human), 22, 547
membrane lipid effects, 22, 360
stimulation of cyclic AMP in cultured neuroblastoma, 21, 664
synthesis, inhibition (toad), 21, 142
synthetase
-catalyzed activation of phenacetin metabolites, 22, 479
co-oxidation, 21, 133
Protein
brain, synthesis inhibition by morphine (rat), 22, 706
carboxy O-methylation, 21, 181
826 SUBJECT INDEX
Protein-continued
coupling, adenylate cyclase, magnesium regulation (mouse), 22, 267
�nase
activation in parotid gland (rat), 21, 121
cyclic AMP (rat), 21, 121
inhibition, 22, 408
liver, synthesis inhibition by morphine (rat), 22, 706
molecular association with Adriamycin, 22, 158
phosphorylation, in human platelets, 21, 422
synaptosomal, carboxymethyltransferase (calf, rat), 21, 181
Proteolysis, $-endorphin model peptides, 22, 657
Proton gradient, role in biogenic amine storage in platelets (human),22, 94
Psychotropic drugs, inhibition of phencyclidine binding (ray), 22, 72
Pumiliotoxin-C, effect on neuromuscular transmission, 22, 565
Pyrimidine
antifolate derivative, metabolic inhibition (mouse), 22, 766
fluorinated derivative, cytoxicity in L1210 cultures, 22, 760
nucleotide, biosynthesis, 21, 224
Pyrromycin, effect on cytoplasmic RNA in erythroleukemia cells, 22,
152
Pyruvate dehydrogenase, oxytocin stimulation (rat), 22, 381
QQuantum chemical analysis, structure-activity relationships, 22, 525
Quantum mechanical analysis, clonidine, 21,400
Quaternary ammomum
agonists and antagonists (ray), 22, 63
drugs, interactions in Torpedo electric organ, 22, 63
Quinone inhibition, hepatic (rat), 22, 451
Quinuclidinyl benzilate
binding in brain (mouse), 22, 554
binding in heart (rat), 21, 589
‘H-labeled
binding in astrocytoma cells (human), 22, 310
binding in heart (rat), 21, 581
L-Quinuclidinyl benzilate, 3H-labeled, heterogeneity of binding sites in
synaptosomal membrane (cat), 22, 304
R
Radical
free, carbon-centered (rat), 22, 239
hydroxyl, production, 21, 262
Radioligand binding, computer modeling, 21, 5
Receptor
acetylcholine
drug specificity (ray), 22, 63
in soleus muscle (rat), 22, 565
ionic channel (frog), 22, 636
neuromuscular junction (frog), 22, 636
nicotinic, 21, 351
adenosine A,
binding heterogeneity (rat, rabbit, guinea pig, calf, human), 22,250
binding in brain (guinea pig, bovine), 21, 329
adenylate cyclase-coupled, anterior pituitary gland (porcine), 22, 298
adrenergic, see Adrenergic receptor
y-aminobutyric acid, modulation of cation binding sites (rat), 22, 327
auto-, in dopamine synthesis (rat), 21, 114
autonomic, in submandibular gland (rat), 21, 27
benzodiazepine
y-aminobutyric acid regulation (mouse), 21, 618
chloride channel regulation (mouse), 21, 618
heterogeneity (mouse), 21, 618
in brain (rat), 22, 327
interaction with barbiturates, 21, 320
interconvertible conformations (rat), 21, 57
ion regulation (mouse), 21, 618
membrane-bound (rat), 21, 57
temperature dependence of interaction (rat), 22, 20
binding
$-endorphin models, 22, 657
guamne nucleotide regulation (hamster), 22, 320
monovalent cations (hamster), 22, 320
central nervous system, in vitro, 21, 315
cholinergic muscarinic (mouse), 22, 554
synaptosomal membrane (cat), 22, 304
cholinergic nicotinic (mouse), 22, 554
complexes, in brain (rat), 22, 327
coupling
adenylate cyclase (bovine), 21, 52
adenylate cyclase, allozyme hypothesis, 22, 580
N-ethylmaleimide (rat), 21, 570
cross-linking, 21, 558
-cyclase coupling (mouse), 22, 204
cyclic AMP, in erythrocytes (turkey), 21, 503
digitalis, light-enhanced inhibition of binding (rat, guinea pig), 22,
687
dopamine
affinity states (porcine), 22, 298
anterior pituitary gland (porcine), 22, 290, 298
D-1, characterization (rat), 22, 281
D-2 (bovine), 21, 44, 52
D-3 (bovine), 21, 44, 52
subtypes (bovine), 21, 44, 52
two affinity states (porcine), 22, 290
-drug interactions, nonspecific, 22, 725
-effector coupling, in platelets (human), 21, 609
estrogen, translocation by SKF 525-A (rat), 21, 533
[3Hjetorphine, binding in vivo (rat), 21, 272
glutathione, peptide interaction (hydra), 21, 629
guanine nucleotide regulation (rat), 22, 532
histamine
characterization in vas deferens (mouse), 22, 602
in polymorphonuclear neutrophils (human), 21, 78
myocardial (human), 21, 671
sensitivity to H, and H2 agonists and antagonists (mouse), 22, 602
inhibition of platelet adenylate cyclase (human), 22, 574
insulin’
adipocyte, effects of adenosine (rat), 22, 614
erythrocyte, regulation by insulin and concanavalin A (frog), 22,
619
interactions, thermodynamics (rat, rabbit, guinea pig, caff, human),
22, 250
ionic channel (frog), 21, 637
kinetics, reserve, 22, 369
-mediated inhibition, adenylate cyclase (rat), 21, 570
multiple, in brain (rat), 22, 327
muscarinic
antiestrogen interaction (rat), 21, 287
binding of acecidine and its methiodide (rat), 21, 594
cardiac (rat), 21, 581, 589
central (cat), 22, 304
muscarinic cholinergic
activation of phosphodiesterase, 22, 310
characterization (porcine), 21, 66
effect of phencycidine (frog), 21, 637
interaction with guanine nucleotide binding component (rat), 21,
570
in vivo regulation (chick), 21, 280
on cultured thyroid cells (porcine), 21, 66, 73
nicotinic
effect of N-alkyl analogues of amantadine (frog, ray), 22, 82
effect of phencycidine (frog), 21, 637
nicotinic acetylcholine
binding sites (ray), 22, 72
channel, interactions with {‘3H]phencyclidine (ray), 22, 72
SUBJECT INDEX 827
messenger
ion channel, 21, 351
ionic channels, interaction with N-alkyl analogues of amantadine
(ray), 22, 82
neuromuscular (frog), 22, 636
receptor/channel, binding (ray), 22, 63
nicotinic cholinergic, in brain (rat), 22, 56
occupancy/effect relationship, 22, 574
opiate
binding, 21, 483, 492
binding, effect relationship (rat), 21, 272
binding in brain (rat), 21, 564
binding models (rat), 21, 272
binding sites, 21, 266
caudate nucleus, etorphine binding (sheep), 22, 648
delta, 21, 558
desensitization, 22, 1
down regulation, time course, 22, 1
in neuroblastoma x glioma NG1O8-15 hybrid cells, 22, 1
membrane lipid effects, 22, 360
multiple (rat), 21, 564
multiple, coupling in vitro, 21, 548
multiple, in brain (rat), 21, 538
multiple sites, 21, 266
various brain areas (rat), 22, 389
opioidallosteric effects, 21, 548
allosteric effects (rat), 21, 538
two-state binding model (rat), 22, 349
oxytocin, adipocyte (rat), 22, 381
presynaptic, conformational requirements, 21, 259
prostaglandin
E2, adipocyte (hamster), 22, 320
in promyelocytic leukemia cells (human), 22, 547
membrane lipid effects, 22, 360
regulation
cations (guinea pig, bovine), 21, 329
guanine nucleotide (guinea pig, bovine), 21, 329
saxitoxin, 21, 343
serotonin, characterization in brain (rat), 22, 243
site
delta-opiate, 21, 266
kappa-opiate, 21, 266
mu-opiate, 21, 266
sigma-opiate, 21, 266
sodium regulation (rat), 22, 532
substance P, in mesencephalic cells (mouse), 22,48
subtypes, computer modeling method for binding data, 21, 5
surface, for histamine (human), 22, 547
Torpedo electric organ, 22, 63, 72
turnover in cultured thyroid cells (porcine), 21, 73
Rectification, delayed (frog), 21, 637
Reductase
cytochrome P-450, hepatic microsomal (rabbit), 22, 471
ribonucleotide, inhibition (human), 21, 474
Reduction, microsomal, gentian violet (rat), 22, 239
Regulation, enzyme secretion in parotid gland (rat), 21, 121
Regulatory site, antagonist, 22, 231
Relaxation rates, T,, substrate-cytochrome P-450 complexes (rabbit),
21, 701
Renal cortex
adenylate cyclase-coupled alpha2-adrenergic receptors (rat), 22, 589
alpha-adrenergic receptors (rat), 22, 532
Ribonucleotide reductase, inhibition (human), 21, 474
Rifamycin, C(3) derivatives, 21, 394
Ho 5-4864, 3H-labeled, characterization of benzodiazepine binding sites
(rat), 22, 26
RNA
cytochrome P,-450 (mouse), 22, 779
effect of anthracyclines, 22, 152
nuclear
colon carcinoma cells in culture (human), 21, 468
transport, 22, 152
polyadenylation, inhibition, 22, 517
polymerase, DNA-dependent, inhibition by rifamycin, 21, 394
synthesis
adenovirus, 22, 517
effects of ademne nucleosides, 22, 517
in cultured colon carcinoma cells (human), 21, 468
total, effect of anthracyclines, 22, 152
R0t analysis, hepatic cytochrome P,-450 (mouse), 22, 779
RU-24926, see 3,3’-[(Propylimino)di-2,1-ethanediyl]bis[phenol]
S
5180 AT/3000 cell, dihydrofolate reductase (mouse), 21, 231
Sarcoplasmic reticulum, cardiac
Ca2�-ATPase (bovine), 22, 8
effect of halothane (bovine), 22, 8
Saxitoxin
binding site, structure, 21, 343
nonspecific binding, 21, 343
receptor, 21, 343
Sc”4, inhibition of adenylate cyclase (mouse), 22, 274
Scatchard linearization, 21, 564
Secretin, effect on cardiac adenylate cyclase activity (rat), 22, 342
Secretion
enzyme
in parotid gland (rat), 21, 121
regulation (rat), 21, 121
prolactin
anterior pituitary gland (porcine), 22, 298
control (porcine), 22, 290
stimulus-induced, in human platelets, 21, 422
Secretory granule, isolated, calcium transport (mouse), 22, 715
Sedatives, interaction with benzodiazepine receptors, 21, 320
Selectivity
colon xenografts (human), 22, 771
for delta opiate receptor, dimeric enkephalins, 21, 558
subunit, in tetrameric hemoglobin (rabbit), 21, 1
Sensitivity
heat, pituitary dopamine receptors (porcine), 22, 298
insulin, modulation by adenosine (rat), 22, 614
Serotonin
receptor, characterization in brain (rat), 22, 243
uptake, characterization, 21, 362, 368
Serotonin-2
binding sites, selective 3H-ligand for (rat), 21, 301
receptor binding sites (rat), 21, 301
Serum, human
albumin, characterization of drug binding area, 21, 387
binding to warfarin, 21, 100
interaction with cephalosporins, 21, 92
Sex differentiation, cytochrome P-450 (rat), 22, 795
Sexual differences, drug metabolism (rat), 21, 744
Skeletal muscle
action potential (frog, ray), 22, 82
carbonic anhydrase, carbon dioxide hydration activity (cat), 22, 211
SKF 525-A, see $-Diethylaminoethyl-2,2-diphenylpentanoate
SKF 10047, binding sites, 21, 266
Skin, neonatal, drug metabolism (rat), 21, 239
Sodium
channel
batrachotoxin binding, 22, 627
binding site in nerve membrane, 21, 343
conformation, 21, 343
828 SUBJECT INDEX
Sodium-continued
channel-continued
mutagenic effect, 22, 196
neuroblastoma variants, 22, 196
variants, 22, 196
effect on agonist and antagonist interactions with platelet alpha2-
adrenergic receptor (human), 21, 609
effect on binding in purified platelet membranes (human), 21, 600
fluxes, in erythrocytes (turkey), 21, 503
ion, role in adenylate cyclase inhibition (rat), 22, 589
regulation of receptors (rat), 22, 532
Solubiity, lipid, ethanol, 22, 133
Solubilization, serotonin receptors in brain (rat), 22, 243
Somatostatin, effect on polymorphorphonuclear neutrophils (human),
21, 78Species heterogeneity, adenosine receptor binding (rat, rabbit, guinea
pig, calf, human), 22, 250
Spectroscopy, pulmonary cytochrome P-450 (rabbit), 22, 221
Spin trap, superoxide, 21, 262
Spiperone, binding in brain (rat), 22, 243
Spiroperidol, “H-labeled
binding in pituitary (porcine), 22, 290, 298
binding to caudate nucleus (calf), 22, 281
dopamine receptor binding (bovine), 21, 44, 52
Stability, epoxide, polycyclic aromatic hydrocarbons, 22, 459
Statistical analysis, computer modeling method, for radioligand binding
data, 21, 5
Stenosis, aortic, effect on cardiac muscarmnic receptors (rat), 21, 589
Stenotomus chrysops, cytochrome P-450 and monooxygenase activity
in cardiac microsomes, 21, 517
Stereoselectivity
differential, methotrimeprazine enantiomers, 21, 315
metabolism , chrysene 1,2-dihydriols (rat), 22, 182
Stereospecificity, carbomethoxy at position 10, 21, 196
Stilbene oxide, trans-, enzyme induction (rat), 21, 511
Striatum, catecholamine uptake system (rat), 21, 374
Structure-activity relationship
alkyl-substituted -y-butyrolactones (mouse, guinea pig), 22, 444
alkyl-substituted succinimides (mouse, guinea pig), 22, 444
amantadine (ray), 22, 82
anthracycline molecule, 21, 196
Ca2�-calmodulin complex, 22, 403
dopamine agonists (rat), 22, 281
in ansamycins, 21, 394
picrotoxinin (mouse, guinea pig), 22, 444
quantitative, 22, 725
anxiolytic drugs, 22, 11
molecular shape analysis, 21, 187
quantum chemical analysis, 22, 525
transport sites, hypothalamic and striatal catecholamine uptake, 21,
374
Submandibular gland, regulation of autonomic receptors (rat), 21, 27
Substance P
‘25I-labeled derivative, binding to mesencephalic cells (mouse), 22,48
receptors, in mesencephalic cells (mouse), 22, 48
Substituent constants, theorem, 22, 725
Substrate
amine pump (rat), 21, 374
dopamine inhibition, in striatum and hypothalamus (rat), 21, 374
Subunit selectivity, in tetrameric hemoglobin (rabbit), 21, 1
Succinimides, alkyl-substituted, structure-activity relationships
(mouse, guinea pig), 22, 444
Sulfation rates, 7-hydroxycoumarin (rat), 22, 509
Sulfhydryl group, effects on adenylate cyclase activation (dog), 22, 595
Sulfidocyclophosphamide, cytotoxicity, synergism with misonidazole
(mouse), 22, 175
Sulfite, horseradish peroxidase-hydrogen peroxide oxidation, 22, 732
Sulfonamide, inhibition of skeletal muscle carbonic anhydrase (cat),
22, 211
Sulfonylureas, hypoglycemic, Ca2� ionophoretic activity (mouse), 22,
715
Sulfoxidation
effect on neuroleptic potency of chlorpromazine, 21, 409
effect on neuroleptic potency of methotrimeprazine, 21, 409
Sulfoxide, metabolites, 21, 409
Sulfur dioxide, aqueous, sulfur trioxide radical anion, 22, 732
Sulfur trioxide, radical anion, direct detection during oxidation of
sulfite, 22, 732
Superoxide
hepatic microsomal (rabbit), 22, 471
spin-trapped adducts, 21, 262
Synaptic plasticity, 21, 280
Synaptosome
calcium uptake (rat, mouse), 22, 99
hypothalamic (rat), 21, 181
uptake system, 21, 374
membrane
cholinergic muscarmnic receptor (cat), 22, 304
potential (rat, mouse), 22, 99
striatal, uptake system (rat), 21, 374
Synergism, cytotoxic, misonidazole and sulfidocyclophosphamide(mouse), 22, 175
Synthetase, prostaglandin, co-oxidation, 21, 133
Synthesis, prostaglandin, inhibition (toad), 21, 142
T
Tamoxifen binding, cooperativity studies (rat), 21, 287
Temperature
dependence, benzodiazepine-receptor interaction (rat), 22, 20
effect on [“Hiflunitrazepam binding (rat), 21, 57
Terbium fluorescence, 22, 105
2,3,7,8-Tetrachlorodibenzo-p-dioxin, induction of cytochrome P,-450
mRNA (mouse), 22, 779
Tetrahydro-fJ-carboline, effect on membrane fluidity, 22, 721
Tetramethylammonium, agonist action (ray), 22, 63
Tetrapeptide, opiate, conformational-energy studies, 22, 667
Thermodynamics
benzodiazepine binding (rat), 22, 20
receptor interactions (rat, rabbit, guinea pig, calf, human), 22, 250
Thermotropic properties, dipalmitoylphosphatidylcholine, 22, 133
Thiono-sulfur-containing compounds, effect on liver (rat), 21, 464
Thrombin, platelet protein phosphorylation (human), 21, 422
Thymidine
kinase
inhibition, 22, 231
regulation, 22, 231
rescue effects in methotrexate-treated cells (human), 21, 718
rescue, in methotrexate-treated cells (human), 21, 718
triphosphate, inhibition, 22, 231
Thymidylate kinase, virus-coded, 21, 432
Thymidylate synthetase
activity in L1210 ascites cells, 22, 760
blockers, 21, 224
levels in gastrointestinal tumor cells (human), 21, 723
Thymus
nuclear histones, effect of methylmercury(II) (calf), 22, 121
synaptosomal protein carboxymethyltransferase (calf), 21, 181
Thyroid
cell
culture (porcine), 21, 66, 73
muscarmnic cholinergic receptors on (porcine), 21, 66, 73
effect on cardiac muscarinic receptors (rat), 21, 589
Thyrotropin-stimulated cyclic AMP, in cultured thyroid cells (porcine),
21, 66
Time delay, cyclic AMP accumulation in lymphoma cells, 22, 609
Tissue, normal limiting (human), 22, 771
SUBJECT INDEX 829
Zinc, glucagon binding, 22, 105
Torpedo
electric organ
drug interactions, 22, 63
receptors, 22, 72
electroplax, receptors, 22, 82
Toxicity, see also Cytotoxicity
cardiac, anthracydline antineoplastic agents (rabbit), 22, 471
pulmonary, 4-ipomeanol (rabbit), 22, 738
renal, phenacetin metabolites, 22, 479
Toxin
bound molecules, exchange of tritium, 21, 343
cholera
ADP ribosylation (mouse), 22, 204
effect on cardiac adenylate cyclase activity (rat), 22, 342
Temor, muscarinic agonist-induced (rat), 21, 594
Triarylmethane dye, cytochrome P450-dependent reduction (rat), 22,
239
Trifluoperazine, effect on human platelets, 21, 422
Tritium
back exchange, saxitoxin, 21, 343
exchange, from bound toxin molecules, 21, 343
Tryptamine, effect on membrane fluidity, 22, 721
Tumor
-derived methionine adenosyltransferases, differences in active-site
and potential target (rat), 22, 752
gastrointestinal
cytotoxicity of 5-fluorodeoxyuridine and methotrexate (human),
21, 723
thymidylate synthetase levels (human), 21, 723
Tyrosine aminotransferase, hepatic, effect of pregnenolone- 16a-carbo-
nitrile (rat), 21, 753
Tyrosine hydroxylase
effect on dopamine synthesis (rat), 21, 114
induction by glucocorticoids (mouse), 22, 421
U
Uptake, norepinephrine, inhibition by xylamine, 21, 380
Uracil, DNA incorporation, 21, 211
Uterus, estrogen receptor (rat), 21, 533
V
van’t Hoff plot, nonlinear, flunitrazepam (rat), 22, 20
Varicella zoster virus, inhibition by (E)-5-(2-bromovinyl)-2’-deoxyrur-
idine, 21, 432
Vas deferens
binding of $-endorphin, models (rat), 22, 657
histamine receptors (mouse), 22, 602
Vasopressin, effect on urinary bladder (toad), 21, 142
Vinblastine
Ca2ttransport ATPase inhibition (human), 22, 413
effect on water flow in urinary bladder (toad), 21, 142
Vinca alkaloids, Ca2�-transport ATPase inhibition (human), 22, 413
Vincristine, Ca2�-transport ATPase inhibition (human), 22, 413
Vindesine, Ca2�-transport ATPase inhibition (human), 22, 413
Virus
herpes simplex, inhibition by (E)-5-(2-bromovinyl)-2’-deoxyruridine,
21, 432
varicella zoster, inhibition by (E)-5-(2-bromovinyl)-2’-deoxyuridine,
21, 432
Voltage clamp
effect on nicotinic acetylcholine receptor (frog, ray), 22, 82
neuromuscular junction (frog), 22, 636
Voltage-sensitive ion channels, nicotinic acetylcholine receptor, 21, 351
W
Walker 256 carcinoma (rat), 21, 729
Warfarin
-albumin interaction, equilibrium and kinetics, 21, 100
binding to human serum albumin, 21, 100
high-affinity binding sites, 21, 387
Water flow, in urinary bladder (toad), 21, 142
x
Xanthines, binding in brain (rat, rabbit, guinea pig, calf, human), 22,
250
Xenograft
colon adenocarcinoma (human), 22, 771
colon, selectivity (human), 22, 771
X-Ray, structure determinations
chiorpromazine, 21, 409
imidazolidines, 21, 400
Xylamine
chemical transformations in solution, 21, 380
inhibition of norepinephrine uptake, 21, 380
Y
Yohimbine
“H-labeled
alpha2-adrenergic receptors, 21, 17
binding in renal cortex (rat), 22, 532
characterization of adenylate cyclase-coupled alpha�-adrenergic
receptors (rat), 22, 589
use as radioligand (human), 22, 574
z
1�
U.S. POSTAL. SERVICE
STATEMENT OF OWNERSHIP, MANAGEMENT AND CIRCULATION(Rqulrsd by 39 U.S.C. 3685)
1. TiTLE OF PUBLICATION
Molecular PharmacologyISSN A. PUBLICATION NO. 2. DATE OF FILING
� J� I 2 � 6 � 819 � � X 10/1/82
3. FREQUENCY OF ISSUE.
Bi-monthly
A. NO. OF ISSUES PUBLISHED B. ANNUAL SUBSCRIPTIONANNUALLY PRICE
6 Personal : $65.00Institutional: $130.01
4. COMPLETE MAILING ADDRESS OF KNOWN OFFICE OF PUBLICATION (Stri(, City, County, Stat. and ZIP Cod.) (Not prlnts.rs)
9650 Rockville Pike Bethesda, Maryland 20814
5. COMPLETE MAILING ADDRESS OF THE HEADQUARTERS OR GENERAL BUSINESS OFFICES OF THE PUBLISHERS (Not prlnt#{149}fs)
9650 Rockville Pike Bethesda, Maryland 20814
t FULL NAMES AND COMPLETE MAILING ADDRESS OF PUBLISHER. EDITOR. AND MANAGNG EDITOR (This It�n MUST NOT b. blank)
PUBLISHER (Nama and CompIf#{149}MblIbsgAddr.sa)
The American Society for Pharmacology 9650 Rockville Pikeand Experimental Therapeutics Bethesda, Maryland 20814
EDITOR (Nan* and CompI�. MailIng Addr.a)
Dr. Norman Kirshner Duke University Medical SchoolPharmacology Department Durham, North Carolina 21202
MANAGING EDITOR (Nama �,d CompM(#{149} M&Ilng Addrass)
Kay A. Croker, Executive Officer 9650 Rockville PikeAmerican Society for Pharmacology & Experimental Therapeutics Bethesda, Maryland 20814
7. OWNER (If owned by a corporation, its name and address must be stated and also immediately thereunder the names and addresses of stockholdersowning or holding 1 percent or more of total amount of stock. If not owned by a corporation, the names and addresses of the individual owners must
be given. If owned by a partnership or other unincorporated firm, its name and address, as well as that of each individual must be given. If the publica-
tion is published by a nonprofit organization, its name and address must be stated.) (Item must be completed)
FULL NAME COMPLETE MAILING ADDRESS
American Society for Pharmacoloqy#{225}#{241}��xperimenta I neraoeutics
FULL NAME
9650 Rockville Pikebetnescia. Maryland �Uli14
8. KNOWN BONDHOLDERS. MORTGAGEES, AND OTHER SECU
TOTAL AMOUNT OF BONDS. MORTGAGES OR
R�TY HOLDERS OWNING OR HOLDING 1 PERCENT OR MORE OF
OTHER SECURITIES (It thr ar none, ao state)
9. FOR COMPLETION BY NONPROFIT ORGANIZATIONS AUTHORIZED TO MAIL AT SPECIAL RATES (Section 411.3, DMM only)The purpose, funct,on. and nonprofit status of fhis organizafion and the exem t status for Federal income tax purposes (Check on.)
(1) (2)r��i HAS NOT CHANGED DURING -- HAS CHANGED DURING (II changed, publlshr must submIt explanation ofL.AJ PRECEDING 12 MONTHS U PRECEDING 12 MONTHS change with this statement.)
10. EXTENT AND NATURE OF CIRCULATtONAVERAGE NO. COPIES EACHISSUE DURING PRECEDtNG
12 MONTHS
ACTUAL NO. COPIES OF SINGLEISSUE PUBLISHED NEAREST TO
FILING DATE
A.TOTALNO.COPIE5(Nifprsisflun) 2112 2175
8. PAID CIRCULATION1. SALES ThROUGH DEALERS AND CARRIERS. STREETVENDORS AND COUNTER SALES none none
2. MAIL SUBSCRIPTION
1665 1782
C. TOTAL PAID CIRCULATION (Sum of 1081 and 1�2)i 665 1782
D. FREE DISTRIBUTiON BY MAIL, CARRIER OR OTHER MEANSSAMPLES, COMPLIMENTARY. AND OTHER FREE COPIES 86 75
E. TOTAL DISTRIBUTION (Sum ol C and 0) 1 7 5 1 1857
F. COPIES NOT DISTRIBUTED1. OFFICE USE, LEFT OVER, UNACCOUNTED, SPOILEDAFTER PRINTING
36 1 318
RETURN FROM NEWS AGENTS none none
G. TOTAL (Sum of E. Fl and 2 - should equal net press run shown in A) 2 1 1 2 2175
SIGNATUR/AND TITLE OF EDITOR. PU8LISHER. BUSINESS11. I certify that the statements made by�’�J MANAG ,OR OWNER
me above are correct and complete � ((� Q � I �
COMPLETE MAILING ADDRESS
INSTRUCTIONS TO AUTHORS
assigned exclusively to the Society for Pharmacology and Experi-
Molecular Pharmacology will publish the results of investigations that shed significant light on drug action
or selective toxicity at the molecular leveL The term “drug” is defined broadly to include chemical agents that
selectively modify biological function.
Suitable papers are those which describe applications of the methods of biochemistry, biophysics, genetics,
and molecular biology to problems in pharmacology or toxicology. Also suitable are reports of fundamental
investigations which, although not concerned directly with drugs, nevertheless provide an immediate basis for
further study of the molecular mechanism of drug action. Observations of phenomena that shed no light upon
underlying molecular interactions are not regarded as appropriate for publication.
Specific areas of interest include: stereochemical, electronic, and other parameters of drug architecture;
conformational analysis of receptors and their function; drug-enzyme and other interactions between drugs and
macromolecules; drug effects upon gene replication and transcription and on protein synthesis; mechanism of
action of antibiotics and other growth-inhibitory drugs; induction by drugs of changes in macromolecular
structure or allosteric transitions; drug-induced alterations in metabolic pathways; effects of hormones and
other drugs on cellular regulatory mechanisms; chemical mutagenesis, carcinogenesis, and teratogenesis;
pharmacogenetics, idiosyncrasies, and drug allergies; selective toxicity in a single organism or in different species;
drug actions on properties and functions of membranes; mechanisms of drug metabolism; distribution and
transport of drug molecules between biological compartments.
“Short Communications” will be considered for rapid publication if their subject matter lies within the scope
of the Journal, if they are concise, and if they are considered to be of sufficiently immediate importance to the
work of other investigators to justify accelerated publication. They may contain experimental observations,
theoretical material, or significant comment upon published investigations.
Page charges. Authors will be billed at the rate of $30.00 per
page after the paper has been published. It is expected that the page
charge will be paid if funds are available for that purpose from the
author’s institution or from the sponsor of this research. Payment
of the charge is not a condition for publication. Neither the editors
nor the reviewers will have knowledge as to who has paid the
charge, and this payment always will be considered entirely volun-
tary.
Submission ofmanuscript. Manuscripts are published in English
only and should be sent to the Editor, Dr. Joel Hardman, Editor,
Molecular Pharmacology, Department of Pharmacology,
Vanderbilt University Medical Center, Nashville, Tennessee
37232, U. S. A. Manuscripts should be typewritten double-spaced
with ample margins on one side of the paper, 8#{189}x 11 inches (ca.
215 x 280 mm). Submit four complete copies of the manuscript and
four copies of each figure, plus one original drawing or photograph
of each figure. Each half-tone figure requires four original drawings
or photographs. All pages should be numbered consecutively begin-
ning with the title page. Limit your reference listings to the minimal
number required to adequately document the manuscript. In most
instances 30 references or fewer should suffice.
Under usual circumstances reviewers will be instructed to return
only their comments to the editorial office and to destroy manu-
scripts after a fmal decision on their acceptability has been made.
Original figures and single copies of manuscripts not accepted for
publication will be returned to the authors upon request.
It is understood that the manuscripts and the results they contain
will not have been published previously and are not being submitted
elsewhere. Manuscripts are accepted for review with the under-
standing that all persons listed as authors have given their approval
for the submission of the paper; further, that any person cited as a
source of personal communications has approved such citation.
Written authorization may be required at the Editor’s discretion.
Articles and any other material published in Molecular Pharma-
cology represent the opinions of the author(s) and should not be
construed to reflect the opinions of the Editor(s) and the Publisher.
If and when a manuscript is published, it will become the sole
property of the Journal.
Authors submitting a manuscript do so on the understanding that
if it is accepted for publication, copyright in the article, including
the right to reproduce the article in all forms and media, shall be
mental Therapeutics. No reasonable request by the author for
permission to reproduce any of his or her contributions to the
journal wifi be refused.
Organization and style ofmanuscripts. The policy of the Journal
is to allow authors maximum freedom in organizing and presenting
their material, and in expressing their ideas, provided only that
clarity and conciseness are achieved.
Certain conventions must be observed. Chemical and mathemat-
ical formulas and abbreviations should follow the Instructions to
Authors ofthe Journal ofBiological Chemistry (Vol. 256, pp. 1-11,
January 10, 1981). Drugs must be referred to by their generic or
chemical names throughout the text, but may be identified by trade
name in parentheses or a footnote. The systematic name and
number given by the Commission on Enzymes of the International
Union of Biochemistry should be included for each enzyme of
importance in a paper, at the point in the Summary or Introduction
where the enzyme is first mentioned. The use of abbreviations
should be minimized and abbreviations avoided in the Summary.
All essential abbreviations should be defined in a single footnote
when first introduced. Abbreviations of journal names should con-
form to the style of BiologicalAbstracts. References to papers that
have been accepted for publication, but have not appeared, should
be cited like other references with the abbreviated name of the
journal followed by the words “in press.” Copies of such papers
should be sent whenever the findings described in them have a
direct bearing on the paper being submitted for publication. “Per-
sonal Communications” and “Unpublished Observations” should be
cited in footnotes to the text and should not be included in the
reference list.
A manuscript should include the following, in the order listed: (1)
Title. Numbered footnotes to the title should be avoided; acknowl-
edgment of financial support should be given in an unnumbered
footnote to the title. (2) Names of authors, their laboratory and
institution. (3) A running title, not exceeding 60 characters and
spaces. (4) Summary. (5) Text. Footnotes should be referred to by
superscript numbers and references by numbers in parentheses. (6)
References, numbered according to order of citation in the text,
including title and complete pagination. Examples: 1. Goren, J. H.,
L. G. Bauce, and W. Vale. Forces and structural limitations of
binding of thyrotropin-releasing receptor: the pyroglutamic acid
moiety. Mol. Pharmacol. 13:606-614 (1977). 2. Sandler, M. Varia-
tions in monoamine oxidase activity in some human disease states,
in Monoamine Oxidase and Its Inhibition. Ciba Foundation Sym-
posium 39. Elsevier, Amsterdam, 327-340 ( 1976). (7). Footnotes,
numbered according to order of appearance in the text. (8) Tables.
(9) Figures. (10) Legends to figures. (11) Name and address of
person to receive galley proof.
Tables. These should be numbered with arabic numerals and
designed to fit the single-column width of the full-page width. Every
table should have an explanatory title and sufficient experimental
detail in a paragraph following the title to be intelligible without
references to the text (unless the procedure is given in the Methods
section, or under another table or figure). Footnotes to tables should
appear beneath the tables themselves and should be designated by
lower-case italic superscript letters, a, b, c, etc.
Figures. These should be numbered with arabic numerals. Each
of the four manuscript copies should contain all of the figures. Only
the orignal set need be of quality suitable for reproduction except in
the case of half-tones, which require four sets of photographs or
original drawings. These should be unmounted glossy photographs
(or original India-ink drawings). Usually figures will be reduced to
one column width (85 mm) and all numbers after such reduction
should be at least 1.5 mm high. The figures must be ready, in all
respects, for direct reproduction: no lettering or other art work will
be done by the publisher. If symbols are not explained on the face
of the figure, only standard characters, of which the printer has
type, may be used (x, 0, #{149},El, �, �, A, C). The back of each
photograph should bear its number, and the legend TOP at the
appropriate edge. The list of legends for the figures should give
captions and sufficient experimental detail, as required for tables.
Galley proof. The cost of all changes on galley proof, other than
printer’s errors, will be charged to authors. The Editors are very
much interested in having accepted contributions appear in the
earliest possible issue of the Journal, and therefore request that
galley proof be returned within 24 hours after its receipt. In excep-
tional cases, a “Note added in proof” may be attached and will be
published if the Editor approves.
Reprints and page charges. An order form for reprints as well as
information on the estimation of page charges will be mailed with
galley proof. Please direct questions on reprints, page charges, or
other business matters to Kay Croker, Executive Officer, American
Society for Pharmacology and Experimental Therapeutics, 9650
Rockville Pike, Bethesda, Md. 20814. Telephone (301)530-7060.